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In 2006, human Trans-Active Regulator DNA Binding Protein (TDP-43) was identified 
as the major ubiquitinated component of inclusion bodies in Amyotrophic Lateral Sclerosis 
(ALS) and Frontotemporal Lobar Degeneration (FTLD), two important neurodegenerative 
diseases in the human population. In ALS/FTLD, TDP-43 that is normally present in the 
nucleus, is found aggregated in the cytoplasm where it is also abnormally phosphorylated, 
poly-ubiquitinated, and cleaved to release toxic C-terminal fragments. Recently, evidences 
of TDP-43 involvement were also reported by our laboratory in Niemann-Pick type C (NPC) 
disease, a Lysosomal Storage Disorder (LDS) with visceral and neurological symptoms. In 
particular, in this disease, the protein TDP-43 does not aggregate in the cytoplasm like in 
the motor neurons of ALS patients. However, it is found mislocalized and abnormally 
phosphorylated in the cytoplasm of three different models: mouse NPC1-/- brain; human 
NPC cellular model (multipotent stem cells derived from skin biopsies, reprogrammed to 
neuronal cells); and in patients’ brain Purkinje cells. 
 Keeping these two observations in mind, the general aim of my work for this thesis 
has been to specifically study one of the major TDP-43 post-translational modifications 
(PTMs), phosphorylation, in two different diseases models: disease-associated TDP-43 
mutations in ALS patients and aberrant phosphorylation of TDP-43 in NPC disease.  
Regarding ALS, together with a group in Indiana/Kansas University I described a 
novel mutation in TDP-43 affecting a Serine residue changing to a Glycine in position 375 
(S375G). The reason why this mutation was interesting is because it was discovered in an 
early-onset ALS case. The results of my study showed that the TDP-43 carrying this S375G 
variant localized more in the nucleus with respect to the wild-type (WT) form. This nuclear 
localization leads to a stronger cytotoxicity probably due to the lack of the phosphorylation 
site, that was suggested to strongly destabilize an amyloid-like structure in its C-terminal tail 
that promoted TDP-43 multimerization. In order to study in depth, the 
physiological/pathological behavior of this Serine residue, I created a cell line expressing 
constitutively the WT, S375G, and S375E (phosphomimic) TDP-43 forms. No significant 
changes were reported in splicing activity, autoregulation, or aggregation, but a cell-cycle 
analysis of the stable clones showed that the number of cells in the G2 phase decreased in 
the two phospho-mutants compared to WT. The exact reason for this alteration is still not 
known. However, preliminary experiments on the mitochondria apoptotic signal that I 
22 
 
performed showed that Apoptosis-Inducing Factor 1 (AIF1) seemed to be released from the 
mitochondria. 
Regarding Niemann Pick C, in order to better understand the molecular mechanisms 
that lead to TDP-43 phosphorylation in NPC, I performed an RNA sequencing analysis using 
a human NPC cellular model and compared the detected list of gene expression changes 
with a list of changes that we previously described for neuronal SHSy5Y cells depleted of 
TDP-43. As described in depth in the thesis, approximately 800 genes were found 
differentially regulated between NPC patients and healthy controls, involving neuronal, 
inflammatory, and lipid metabolism pathway. Among these 800 genes, 64 were found to be 
commonly misregulated in the RNA sequencing performed on SHSy5Y cells upon TDP-43 
silencing. Based on these preliminary results, I identified two particular targets of TDP-43 
that were previously unknown: Inositol 1,4,5-Trisphosphate Receptor Type 1 (ITPR1), and 
the Ependymin Related 1 (EPDR1). Interestingly, the depletion (down regulation) of ITPR1 
gene induced changes in TDP-43 protein cellular localization, thus suggesting a direct link 
between alterations in this gene and aberrant TDP-43 regulation. 
Taken together, the data contained in my thesis strongly support growing evidence 
that alterations of TDP-43 post-translational modifications, either due to disease-associated 
mutations or genes that control its cellular localization, can play a potentially important role 















1.1 Trans-Active Regulator DNA Binding Protein (TDP-43) – general 
characteristics 
 
1.1.1 The TDP-43 gene 
Human TDP-43 was isolated and described for the first time in 1995 as a novel 
transcriptional inactivator involved in the TAR (Tat Activation Response) DNA motive of the 
Human Immunodeficiency Virus (HIV-1) binding (Ou et al., 1995). 
The human gene is located on chromosome 1 in MASP2 (Mammalian-binding lectin 
Serine-Protease 2) locus, a highly conserved gene-rich region [chr1:11,013,728-
11,022,651; 8,924bp] (Fig.1). 
 
Figure 1 - TAR-DNA binding protein locus and position on chr1 - PubMed and UCSC Genome Browser (hg38) 
In Figure 2 is shown the TAR-DNA binding protein (TDP-43) gene structure 
composed of 6 exons: the coding region starts from exon 2 to exon 6, whilst the first one is 
a non-coding exon (Banks et al., 2008; Wang et al., 2004). 
 
Figure 2 - TARDBP coding exons structure (Banks et al., 2008). 
During evolution, TDP-43 has been highly conserved among many species, like 
Drosophila melanogaster, Xenopus laevis and Caenorhabditis elegans (Fig.3) (Ayala et al., 
2005; Stover et al., 2004; Wang et al., 2004). The high sequence conservation in such 
distant organism indicates that this protein has played a fundamental role during evolution 




Figure 3 - Aminoacid sequence alignment of the eukaryotic TDP-43 proteins in different organisms: human (hTDP-43), 




1.1.2 TDP-43 protein structure 
From a structural and functional point of view, TDP-43 belongs to the heterogeneous 
nuclear ribonucleoprotein (hnRNP) family, known to associate with heterogeneous RNA in 
a sequence-specific manner, thanks to the presence of specific domains able to mediate 
protein-RNA interactions and protein-protein interactions. The hnRNP proteins play an 
important role in multiple steps of gene expression regulation including transcription, 
splicing, mRNA stability, DNA replication/repair, protein translation, and export or retention 
of nascent RNA. They are able to interfere with different processes depending on their 
subcellular localization, by binding to RNA, other proteins, or cellular components (Buratti 
and Baralle, 2012; Y. M. Ayala et al., 2008; Krecic and Swanson, 1999). 
The TDP-43 primary structure can be split in three basic domain composition, as 
shown in Figure 4 (Buratti and Baralle, 2012; Krecic and Swanson, 1999).  
 
Figure 4 - TDP-43 protein structure (Buratti and Baralle, 2012). 
- The N-terminal domain (NTD): very little is known about this region. It is very well 
conserved during evolution especially the residues encoding for the Nuclear 
Localization Signal regions, (NLS) composed by NLS1 (K82RK84) and NLS2 
(K95VKR98), mediating the protein nuclear localization. Mutations in those sites 
reduce the presence of TDP-43 in the nucleus (Buratti and Baralle, 2001, 2008; 
Winton et al., 2008; Y. M. Ayala et al., 2008). Recently, the NMR structure of this 
region has been solved and it has been shown to be important in mediating protein 
oligomerization (Mompeán et al., 2016). 
- The RNA-Recognition Motives (RRM): RRMs are two highly-conserved domains 
involved in the binding to specific RNA or DNA sequences and act by mediating the 
nucleic acid direct recognition (Y. M. Ayala et al., 2008; Buratti and Baralle, 2001). In 
particular, the RRM-1 region is necessary and sufficient to mediate binding to UG or 
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TG repeated motifs (Ayala et al., 2005; Buratti and Baralle, 2001). Using 
Electromobility Shift Assay (EMSA), it has been shown that a mutant lacking of this 
region was sufficient to abolish completely the ability of TDP-43 to bind RNA 
molecules (Buratti and Baralle, 2001). Also, RRM-2 region was studied together with 
RRM-1 domain. Using a mutant lacking of RRM-2, it has been discovered that the 
deletion of RRM-2 domain did not compromise completely RNA binding capability of 
the protein, concluding that the two domains have different binding characteristics 
and RRM-2 can help RRM-1 in RNA recognition (Buratti and Baralle, 2001). Recently, 
RRM-2 was described to play a role in chromatin organization by the co-crystallization 
with single-stranded DNA forming thermal-stable dimeric complex (Y. M. Ayala et al., 
2008). Moreover, RRM2 is predicted to contain a nuclear export signal (NES) (Fig. 
4) (Strong et al., 2007; Buratti and Baralle, 2001) that acts together with the NLS 
signal in the N-terminus to determine the nuclear-cytoplasmic balance of TDP-43. 
- The C-terminal Domain (CTD): this sequence mediates protein-protein interaction 
especially with other hnRNPs, promoting the recruitment of TDP-43 to the 
macromolecular complexes that are necessary to carry out its functions. For example, 
by immunoprecipitation and proteomic studies it has been discovered that TDP-43 
can interact with another abundant hnRNP protein, hnRNP A2/B1, through residues 
342 to 366 in the C-terminal tail (Fig.4) (Budini et al., 2012; D’Ambrogio et al., 2009). 
In addition to protein-protein interactions, the C-terminal domain is essential for 
affecting protein solubility and sub-cellular localization. The fact that it is poor in 
charged residues means that pH switches can lead to aggregative phase changes 
and microdroplet formation to bring RNA molecules in the right sub-cellular 
localization. As a consequence, deletions in the CTD lead to large nuclear and 
cytoplasmic aggregates formation (Buratti and Baralle, 2012; Y. M. Ayala et al., 
2008). In fact, even in normal conditions, this region tends to induce TDP-43 
aggregation due to the presence of  glycine-rich motif and a Gln/Asn-rich region 
identified as a potential prion-like domain (Udan and Baloh, 2011). Most importantly, 
the C-terminal tail is strongly linked to the pathogenesis of neurodegenerative 
disorders because this is the region where most of the disease-associated mutations 
associated with Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia 
(FTLD) are localized, except for a few mutations that are located in the RRM domain 




1.1.3 The TDP-43 cellular function 
Due to its structure, TDP-43 is involved in many cellular functions, both in the 
nucleus and in the cytoplasm (Fig.5). 
 
Figure 5 - TDP-43 nuclear and cytoplasmic physiological roles (Buratti and Baralle, 2012). 
First of all, as a typical member of the hnRNP protein family, TDP-43 has been 
shown to be involved in multiple levels of RNA processing, like splicing, transcription, 
transport and translation (Lagier-Tourenne et al., 2010). In particular, TDP-43 is mostly 
known for its involvement in splicing regulation. In Figure 6, several TDP-43 target genes 
are shown characterized by the presence of  an UG-rich region bound specifically by the 




Figure 6 - Examples of TDP-43 target genes (Buratti and Baralle, 2012). 
An example of TDP-43 mechanism of action in regulating the splicing process is 
reported in Figure 7, where TDP-43 is shown binding to one of its best characterized targets, 
the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. In this case, TDP-43 
recognizes specifically the splicing regulatory (UG)m elements located near the 3’splice-site 
of CFTR exon 9 through the RRMs (Buratti and Baralle, 2001, 2008). The RRMs alone are 
not enough to promote splicing regulation; indeed TDP-43 inhibits the recognition of basic 
splicing factors through the Glycine-rich C-terminal domain that recalls other hnRNP 
proteins and together create an inhibitory complex that abolish the assembling of the 





Figure 7 - TDP-43 and hnRNPs complex on CFTR exon 9 (Buratti and Baralle, 2008). 
In physiological conditions, TDP-43 is able to modulate its own protein levels 
through a negative feedback loop by binding its own mRNA in the 3’UTR region, leading to 
mRNA instability and degradation (Buratti and Baralle, 2012; Budini and Buratti, 2011). 
Figure 8 schematically shows the TDP-43 autoregulation mechanism: low concentrations 
of nuclear TDP-43 allow the use of the most efficient poly-A1 site instead the others two, 
pA2 and pA4. On the other hand, abundant TDP-43 protein levels result in the binding with 
sub-optimal sites that lead to the rapid degradation of the mRNA. Using this negative 
feedback mechanism, the TDP-43 concentration within cells can remain constant and 
alterations in this process could be a major driver of aberrant TDP-43 production and 





Figure 8 -TDP-43 autoregulation mechanism (Budini and Buratti, 2011). 
In addition to pre-mRNA splicing, TDP-43 plays also an important role in micro-RNA 
(miRNA) biogenesis (Lee et al., 2012). Although the mechanism through which this occurs 
is still not clearly known, TDP-43 is thought to be involved in the cytoplasmic cleavage step 
of miRNA by interacting with Argonaute-2 and DDX17, two proteins implied in this process 
(Lagier-Tourenne et al., 2010). 
TDP-43 is implicated in mRNA turnover by regulating mRNA levels of different 
genes (Lee et al., 2012). An example is TDP-43 inhibition of Cyclin Dependent Kinase 6 
(CdK6) expression through its recruitment to the GU-rich transcript. The depletion of TDP-
43 in human cells leads to a significantly increase of CdK6 protein and transcript level 
resulting with a major phosphorylation of CdK6 targets (Youhna M Ayala et al., 2008). In 
addition, TDP-43 influences also the expression of the histone deacetylase 6 (HDAC6), a 
protein involved in other proteins aggregation and degradation (Fiesel et al., 2010). TDP-43 
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knockdown/loss leads to HDAC6 downregulation and accumulation of its substrates (Fiesel 
et al., 2010). Another example is the human low molecular weight neurofilament (hNFL), 
where TDP-43 has been shown to stabilize hNFL with a direct interaction of the 3’UTR of 
this mRNA (Strong et al., 2007). TDP-43 binding to hNFL is important for this mRNA 
cytoplasmic translocation and its translation in the correct subcellular compartment (Strong 
et al., 2007). TDP-43 loss or altered function could affect also the regulation of downstream 
genes, that taken together can potentially lead to a disease status (Lee et al., 2011).  
According to its functions, TDP-43 in physiological conditions is present also in the 
cytoplasm working on mRNA destination in the cell’s compartment, subcellular localization, 
translation, and degradation acting as a nucleus-cytoplasmic shuttle (Lagier-Tourenne et 
al., 2010). In particular, TDP-43 was found in RNA transporting granules and, by altering 
mRNA transport and localization, it is involved in neuroplasticity modulation (King et al., 
2012; Lagier-Tourenne et al., 2010). 
Finally, in a rather limited set of examples, TDP-43 is known to interact with DNA, 
in particular with single stranded DNA, acting as transcriptional regulator. Indeed, this 
protein was first discovered as a regulator of studied as a potential regulator of the HIV-1 
TAR DNA sequence motif (Lee et al., 2012; Ou et al., 1995). More recently, it has been 
shown to be involved in the regulation of the spermatid-specific SP-10 gene (ACRV1), 
preventing the enhancer-promoter interaction (Lee et al., 2012). In this particular event, 
TDP-43 interacts with SP-10 insulator, abolishing SP-10 translation. TDP-43 knockdown or 
mutations suppressed this capability. This role is tissue specific, as far as TDP-43 is present 





1.2 TDP-43 proteinopathies 
As previously described, TDP-43 plays an important role in cell metabolism, and in 
particular in the regulation of RNA homeostasis. TDP-43 disfunctions can disrupt RNA 
metabolism with devastating consequences for the cells, especially for neurons in which 
RNA processing events are particularly important to increase their potential ability to 
modulate transcriptome and gene expression (Conlon and Manley, 2017; Sephton and Yu, 
2015). In recent times, considering the increasing number of diseases that are characterized 
by misregulation of TDP-43, a new term has been coined and they are now classified under 
the term of TDP-43 proteinopathies (Barmada and Finkbeiner, 2010). 
 
1.2.1 Neurodegenerative disorders 
As already mentioned, in 2006 TDP-43 was identified for the first time as the major 
ubiquitinated component of inclusion bodies in Amyotrophic Lateral Sclerosis (ALS) and 
Frontotemporal Lobar Degeneration (FTLD) patients’ brain. Under pathological conditions, 
the protein is depleted from the nucleus and sequestered as 
hyperphosphorylated/ubiquitinated insoluble aggregates, disturbing the physiological 
nuclear functions of TDP-43 and its trafficking to the cytosol (Arai et al., 2006; Neumann et 
al., 2006). A brief overview will therefore follow with regards to some of these pathologies. 
 
1.2.1.1 Amyotrophic Lateral Sclerosis – ALS 
Amyotrophic Lateral Sclerosis (ALS) is a fatal motoneuron disease characterized by 
progressive loss of function of the upper and lower motoneurons at the spinal or bulbar level, 
resulting in muscle weakness, atrophy and spasticity (Zarei et al., 2015; Gendron et al., 
2013). 
It was first described in 1869 by the French neurologist, Jean-Martin Charcot, but 
the disease became well known when it was diagnosed in 1939 to Lou Gehrig, a baseball 
player (Zarei et al., 2015). 
ALS is the third most common adult neurodegenerative disease after Alzheimer 
Disease (AD) and Parkinson Disease (PD) (Banks et al., 2008). The incidence of ALS is 
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similar throughout the world, affecting 1.5-2.5 patients per 100000 individuals (Barmada and 
Finkbeiner, 2010). 
The pathology is categorized in two forms: 
- Sporadic (sALS), the most common form which affects 90-95% of the patients with 
no genetic inheritance. 
- Familiar (fALS) type, that includes the remaining 5-10%, associated to genetic 
inheritance factors (Zarei et al., 2015). 
Approximately 20% of all fALS is caused by mutations in the ubiquitously expressed 
enzyme Super-Oxide Dismutase1 (SOD1) and about 1% of sALS are caused by mutations 
in the same gene (Banks et al., 2008). Some recent studies have described another 
prominent genome region where mutations are present in fALS cases, C9orf72 (Cooper-
Knock et al., 2015). 
ALS is a clinically and genetically heterogeneous disorder arising between the fourth 
and the seventh decade, and the median time from symptom onset to death is 30-36 months, 
often due to respiratory muscle involvement. Patients may present a predominantly upper 
motoneuron (UMN) loss, a lower motoneuron (LMN) degeneration, or a combination of the 
two. Some patients can also present an early bulbar involvement but in other cases the 
muscles of the head and neck may be not involved during the disease progress (Barmada 
and Finkbeiner, 2010). 
Most importantly, as disease progresses ALS seems to affect different brain areas, 
from the frontal and temporal cortices, brainstem and cerebellum, adding different symptoms 
to the traditionally recognized motor system degeneration (Barmada and Finkbeiner, 2010). 
 
1.2.1.2 Frontotemporal Lobar Degeneration – FTLD 
Frontotemporal Lobar Degeneration (FTLD) is the most common cause of presenile 
dementia after Alzheimer disease below 65 years (Banks et al., 2008). It is a clinically and 
pathologically heterogeneous syndrome, characterized by a progressive decline in behavior 
or language, associated with degeneration of the frontal and anterior temporal lobes 
(Rabinovici and Miller, 2010). Patients may also display movement abnormalities with 
clinical features overlapping with Motoneuron Disease (MND) that recall ALS characteristics 
(Gendron et al., 2013). 
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First evidence of the disease was described in 1892 by Arnold Pick who studied a 
patient with progressive aphasia and lobar atrophy. In 1911, the presence of neuronal 
inclusions at neuropathological examination, later called Pick bodies, was reported by Alois 
Alzheimer (Seelaar et al., 2011). 
FTLD patients are clinically classified into three different groups depending on the 
early and predominant symptoms, such as a behavioral variant (bvFTD), and two language 
variants, called semantic dementia (SD), and progressive non-fluent aphasia (PNFA). Each 
variant is associated with a different brain atrophy pattern and has peculiar histopathologic 
characteristics. Sometimes the symptoms can overlap, in particular during the later course 
of the disease when it spreads and involves the entire frontal and temporal lobes (Rabinovici 
and Miller, 2010). 
From a histopathological point of view, FTLD patients are characterized by atrophy 
of the frontal and temporal lobes and by the presence of glial and neuronal inclusion bodies 
composed by: TAU, TDP-43, or fused-in-sarcoma (FUS) (Rabinovici and Miller, 2010). FTLD 
patients can be classified in sub-molecular groups depending on the inclusion type: 
- FTLD with TAU inclusion (FTLD-TAU). FTLD tauopathy is characterized by the 
presence of Pick bodies, which are solitary, round or oval, argyrophilic inclusions 
found in the cytoplasm of neurons (Rabinovici and Miller, 2010). 
- FTLD with ubiquitin TDP-43 positive inclusions (FTLD-TDP) is characterized by the 
presence of TDP-43 as the major ubiquitinated component. Like in ALS, under 
pathologic conditions TDP-43 is displaced from the cell nucleus to the cytoplasm, 
hyperphosphorylated, ubiquitinated and cleaved to produce C-terminal fragments 
(CTF) which aggregate and form the inclusion bodies. Neuronal and glial TDP-43 
inclusions are found in the majority of cases previously classified as FTLD-TAU 
negative (FTLD-U) with and without motor neuron disease symptoms (Rabinovici and 
Miller, 2010). 
- FTLD-FUS positive cases cover about the 5–20% of all FTLD-U cases that remain 
negative for TDP-43. FUS is a ubiquitously expressed DNA/RNA binding protein that 
regulates gene expression and, like TDP-43, is also involved in ALS. The clinical 
phenotype is characterized by early onset and important behavior clinical signs 
(Rabinovici and Miller, 2010). 
FTLD patients can also be recognized by the presence or the absence of 
motoneuron disease features: 
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- FTLD with Motor-Neuron Disease (MND) can be also divided in two subtypes: 
presenile dementia with MND or ALS with dementia (Arai et al., 2006); 
- FTLD with MND-type inclusions, but without MND phenotype (Arai et al., 2006); 
- FTLD phenotype lacking of distinct histology, without TAU or ubiquitin-positive 
inclusions (Arai et al., 2006). 
 
1.2.1.3 Motoneuron Disease – MND 
Based on the predominant symptoms, FTLD and ALS could seem two different 
disorders: FTLD is characterized by progressive changes in social behavior or/and language 
dysfunctions whilst ALS shows weakness and wasting of the muscles. However, in some 
cases the two phenotypes can eventually match. For example, some FTLD patients develop 
a MND phenotype and around 1/3 of ALS patients eventually show some form of dementia 
(Neumann et al., 2006). Moreover, families in which the two diseases segregated together 
were identified, speculating a clinical and pathological overlap between the two disorders. 
This hypothesis was confirmed by biochemical and immunohistochemical analyses  
suggesting that they could represent two manifestations of the same basic 
neurodegenerative disorder (Achi and Rudnicki, 2012; Neumann et al., 2006). 
 
1.2.2 TDP-43, RNA-binding proteins, and metabolic disorders 
Interestingly, neurological impairment is also associated with many metabolic 
disorders, such as monogenic diseases characterized by single gene mutations leading to 
metabolic disfunctions, in particular those involving lysosomal pathways (Fiorenza et al., 
2018). Alterations in the lysosomal system can contribute to protein accumulation, a 
classical feature of neurodegenerative disorders. Therefore, Lysosomal Storage Disorder 
(LSD) patients often show early neurodegenerative symptoms recalling ALS and FTLD 
disease (Bahr and Bendiske, 2002). 
In this context, RNA-binding proteins (RBP), like TDP-43, can play an important role 
in the appearance of the neurological disfunction. In particular, they can disrupt axonal 
transport, and cell metabolism through Golgi apparatus fragmentation of by impairing the 
exosome/lysosome pathway (Janas et al., 2016; Jellinger, 2009; Potashkin and Meredith, 
2006). In neuronal cells, the axonal transport through multi-vesicular bodies (MVBs – like 
lysosome and exosome) is directly implicated in synaptic function playing an important role 
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in the intra/inter cellular communication that is fundamental for neuronal homeostasis (Janas 
et al., 2016). In this regard, it is important to note that spatial and temporal mRNA translation 
is a fundamental requirement in neurons because RNA is often associated with RBPs and 
the resulting RNA-RBP complex can be loaded into exosomes to facilitate the axonal 
transport and the correct subcellular translation or localization. Alternatively, the complex 
can be load in the lysosome promoting its degradation (Fig.9) (Paron et al., 2020; Janas et 
al., 2016). 
 
Figure 9 – MVBs cellular pathway. The RNA-RBP complex loaded in the MVBs can follow exosomal secreting pathway 
(sMVB); or the lysosomal degradation pathway (dMVB) (Paron et al., 2020). 
In this context, therefore, lysosomal pathway disfunctions can impair RNA 
metabolism, explaining the neurological features in many LSDs (Conlon and Manley, 2017). 
 
1.2.2.1 Niemann-Pick type C Disease (NPC) 
In this work, I focused my attention on a specific LSD that is known as Niemann-
Pick type C disease (NPC). NPC was described for the first time in the late 1920’s by Albert 
Niemann and Ludwig Pick as a heterogeneous group of LSD, characterized by cholesterol 
storage disfunction with milder visceral symptoms, and a progressive fatal 
neurodegeneration (Vanier, 2010; Ong et al., 2001). 
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Genetically, NPC is an autosomal recessive disorder due to the presence of 
mutations in two genes NPC1 and NPC2 (Vanier et al., 1996). Around 95% of the patients 
display mutations on NPC1, gene whilst the other 5% stroke on NPC2 (Vanier, 2010; Vanier 
and Millat, 2004). 
NPC1 is located on chromosome 18, and its protein was described as a 1278 amino 
acid transmembrane glycoprotein able to associate with the membranes of different 
cytoplasmic vesicles (Storch and Xu, 2009; Higgins et al., 1999). On the other hand, NPC2 
maps on chromosome 14 and it was first studied as Human-Epididymis (HE1) Specific 
protein1, a secretory protein of the human epididymis. Later studies demonstrated that its 
absence or its mutation was correlated with NPC disease (Storch and Xu, 2009; Vanier and 
Millat, 2004). The mature human NPC2 protein is a small soluble 132 amino acid 
glycoprotein able to bind cholesterol with high affinity (Storch and Xu, 2009). 
In physiological conditions, the cholesterol acquired with the diet is transported in 
the blood vessels through the low-density lipoproteins (LDL) that are then internalized by 
the cells exposing the LDL receptor (Brown and Goldstein, 1986). In cells, the endosome 
maturates in the lysosome and in this compartment the mature NPC1 and NPC2 proteins 
cooperate together to carry out correct cholesterol transport. The proposed model suggests 
that NPC2 is binding the cholesterol molecules inside the lysosomes, and through this 
complex, the cholesterol molecule can physically interact with the N-terminal domain of 
NPC1 protein. At this point, NPC1 transports the cholesterol to the trans-Golgi network 
(TGN) thanks to the cooperation of the sterol sensing domain and the C-terminal tail (Fig.10) 
(Estiu et al., 2013; Storch and Xu, 2009; Vanier and Millat, 2004). In this manner, mutations 





Figure 10 – NPC1 and NPC2 lysosomal interaction and cholesterol binding (Paron et al., 2020). 
This model holds true for the visceral organs but not for the brain where the 
cholesterol is synthetized by the astrocyte and oligodendrocytes without any LDL-uptake 
(Björkhem et al., 2004). This clarification is very important because probably the molecular 
mechanism that undergoes to neurodegeneration in NPC disease is more subtle and not 
simply linked to the cholesterol pathway, but more similar to the one occurring in classical 
neurodegenerative disorders (Paron et al., 2020). 
For this reason, NPC disease is not simply limited to visceral symptoms but it can 
be classified as a neurologic and neurodegenerative disorder. It is important to underline 
that the systemic diseases occurs prior to the neurological impairment. In fact, except for 
the perinatal period, NPC systemic disease is not very severe and quite well tolerated in 
most of the patients (Vanier, 2010). 
At present, NPC neuro-pathogenetic mechanisms are still not clear but if we 
consider that RNA metabolism is very well known to be stricter controlled and regulated in 
the nervous system it is likely that the disruption of these pathways can represent a 
promising candidate to explain the pathogenesis of neurodegenerative diseases (Conlon 




1.2.2.2 NPC neurodegeneration and TDP-43 
As previously described, TDP-43 has a fundamental role inside the cells, especially 
regarding RNA metabolism. Relying on this, in 2016 a correlation between NPC and TDP-
43 was established by our lab (Dardis et al., 2016). In this work, Andrea Dardis and 
colleagues found TDP-43 mislocalized in the cytoplasm of Purkinje cells of NPC1-/- mouse 
model and in neuronal cells derived from multipotent stem cells isolated from skin biopsies 
of NPC patients, comparing to healthy controls (Fig.11) (Dardis et al., 2016). 
 
Figure 11 – TDP-43 cytoplasmic mislocalization in NPC human cellular mode. A) TDP-43 staining in wild type neuronal-
like cells. B) NPC neuronal-like cells stained for TDP-43. C) and D) panels are reporting neuronal-like cells stained for a 
neuronal marker (NeuN) respectively wild type and NPC samples  (Dardis et al., 2016). 
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They also discovered that TDP-43 was not just mislocalized but also 
hyperphosphorylated, like in ALS patients (Fig.12) (Newell et al., 2018; Dardis et al., 2016; 
Neumann et al., 2009).  
 
Figure 12 – TDP-43 mislocalization and hyper-phosphorylation in NPC human cellular model. Neuronal-like cells were 
stained with phospho-TDP-43 antibody (against the 409 and 410 Serine) in wild type (A) and NPC (B) samples  (Dardis 
et al., 2016). 
In addition, the expression of genes involved in neuronal survival and neuronal 
differentiation, like TFAP2A, CNTFR, MADD, MEF2D, CTNND1, KIF2, KIF1B, TLE1, TNIK, 
already described in literature as TDP-43 targets, was tested. The observation that 6 out of 
9 genes tested were misregulated, supported the idea that TDP-43 mislocalization could 
play a role in neurodegeneration feature of NPC disease (Fig.13) (Dardis et al., 2016). 
 




1.3 TDP-43 pathogenic mechanisms in neurodegenerative disorders 
After TDP-43 discovery as the major component of the inclusion bodies, many 
efforts have been performed aiming to describe its pathogenic mechanisms. 
In TDP-43 disorders, the protein is found ubiquitinated and hyperphosphorylated, it 
is present in insoluble inclusions or in a C-terminal truncated form (20-25kDa fragments), it 
is mislocalized in the cytoplasm, and a loss of nuclear TDP-43 is detectable. However, the 
border between physiological and pathological aggregation is very subtle: the association 
with RNA, post-translational modification, and the formation of RNA granules is necessary 
to regulate mRNA transport and its final translation, but upon cellular stress this mechanism 
can become pathological with the irreversible aggregation of RNA-protein granules (Conlon 
and Manley, 2017; Vanderweyde et al., 2013). The balance between two cellular 
compartment is very delicate: a small perturbation can lead to the formation of TDP-43 
aggregates that recapitulate TDP-43 pathologies features (Winton et al., 2008). Owing to 
this complexity, it is still unknown which of these processes should be considered primary 
characteristics of the disease and directly linked to neurodegeneration, as opposed to 
represent secondary features or epiphenomena (Lee et al., 2012). 
In general, two models have been proposed to explain TDP-43 pathogenesis: Loss-




1.3.1 Loss-Of-Function mechanism (LOF) 
 
Figure 14 - TDP-43 LOF model leading cell death (Lee et al., 2012). 
The LOF mechanism is thought to occur when cellular stress causes a redistribution 
of TDP-43 in pre-inclusion of the phosphorylated and/or ubiquitinated protein (stress 
granules). The presence of prolonged stress conditions and abnormal post-translational 
modifications eventually makes the aggregates difficult to be degraded. In this model, the 
increase in aggregates numbers/size induce nuclear clearance of the functional protein, the 
formation of truncated C-terminal fragments, and loss of autoregulation. The LOF toxicity is 
therefore induced by the sequestration of functional TDP-43 into the aggregates and 





1.3.2 Gain-Of-Function mechanism (GOF) 
 
Figure 15 - TDP-43 GOF model leading cell death (Lee et al., 2012). 
In addition to aggregation, a prolonged stress condition can also lead to abnormal 
cytoplasmic distribution, aggregation, changes in the autoregulation process, that occurs in 
the nucleus, leading to increas total protein levels (which are known to be toxic), and escape 
from degradation of partially folded protein oligomers by the ubiquitin-proteasome system 
(UPS) (Fig.15) (Lee et al., 2012). All these changes can be considered pathological when 
they have deleterious downstream effects and when the cell is not able anymore to limit their 
toxicity (Barmada and Finkbeiner, 2010). 
 
Finally, it is important to note that these two models are not mutually exclusive and 
together they can cooperate in TDP-43 mediated neurodegeneration (Lee et al., 2012).  
45 
 
1.4 TDP-43 mutations 
Since 2008, many papers have been published describing disease-associated 
mutations in the TDP-43 gene, supporting the idea of TDP-43 direct involvement in 
neurodegenerative disorders, like ALS and FTLD. Even if mutations are sporadic events 
(3% in fALS and 1.5% in sALS), their characterization is important to better understand their 
functional significance and therefore TDP-43 pathogenic mechanisms (Buratti, 2015; Banks 
et al., 2008). Interestingly, mutations can display both LOF and GOF characteristics. 
The presence of pathological TDP-43 mutations may result in a loss of function 
mechanism affecting the protein functions through two hypothetic scenarios:  
- Haploinsufficiency or dominant-negative effect of the mutant protein, in which the 
mutant TDP-43 is not able to carry out the normal functions of the wild type. TDP-43 
pathogenic mutations disrupt the physiological function of the protein and the mutant 
form cannot rescue the normal phenotype.  
- The mutations affect the subcellular localization of the protein. In this situation, the 
mutant TDP-43 is able to reduce the nuclear protein levels by dimerizing with the wild 
type and sequestering it in the cytoplasm (Barmada and Finkbeiner, 2010).  
Also, gain of function mechanisms can be promoted by disease-associated 
mutations resulting in new deleterious functions with TDP-43 aggregation in the neurons. 
These inclusions can acquire toxic functions with lethal downstream effects compromising 
neuronal survival. The molecular pathways involved in this process are unknown, but two 
mechanisms have been proposed: 
- TDP-43 may induce toxicity by abnormal interaction with other cellular components: 
for example, aggregating TDP-43 can sequester cellular factors (other proteins; 
mRNA; etc.) disrupting other important pathways for the maintenance of nuclear 
survival.  
- alternatively, pathogenic TDP-43 mutations may affect the binding of the protein with 
other factors, such as ubiquitin-1, thus interfering with the Ubiquitin-Proteasome 
System (UPS), escaping from the degradation (Barmada and Finkbeiner, 2010).   
In keeping with this view, most TDP-43 pathogenetic mutations lie in the C-terminal 
domain (Fig.16) suggesting that they may affect the protein-protein interaction network, 




Figure 16 -TDP-43 mutations (Buratti, 2015). 
In Figure 16, are reported all TDP-43 mutations already described to this date. Each 
mutation can lead to different alterations from the wild-type protein: for example, some 
mutations have been described to be able to increase aggregation, to change TDP-43 
protein-protein interactions profile, to increase the half-life of the protein or its localization 
(Fig.17). It is important to underline that these functional alterations are not common to all 




Figure 17 - Possible alterations promoted by TDP-43 mutation (Buratti, 2015). 
Nonetheless, the study of single TDP-43 mutations is important because it can 
reveal novel potential pathological pathways that should be examined beyond the mutation 
itself. For this reason, a systematic approach to their study will be important in the future in 





1.5 Post-Translational Modifications (PTMs): TDP-43 phosphorylation 
Like other proteins involved in neurodegenerative disorders, TDP-43 undergoes to 
post-translational modification (PTMs) that can affect its function and cellular status both in 
physiological and pathological conditions (Buratti, 2018; Lee et al., 2012). 
In general, PTMs allow proteins to quickly change their structural and functional 
properties in response to internal and external stimuli. For this reason, analyzing PTMs is 
important for better characterize protein profiles during health and disease conditions, 
potentially improving diagnostic and prognostic capabilities. Moreover, PTM analysis may 
provide potentially new specific therapeutic targets in neurodegenerative diseases (Buratti, 
2018). 
The presence of PTM-modified TDP-43 in ALS and FTLD is an issue that has been 
studied for a long time in TDP-43 proteinopathies. However, for many of these PTMs it is 
still unclear whether these modifications lead to aggregate formation/functional alterations 
or whether they are simply a physiological reaction to a cell stress condition. Whatever the 
case, the most prevalent modifications affecting TDP-43 in the ALS/FTD spectrum are as 
follows: phosphorylation; generation of C-terminal domain (CTD) fragments; ubiquitination; 
acetylation; cysteine oxidation; SUMOylating (Buratti, 2018; Lee et al., 2012). In Figure 18 
are summarized all the PTMs involved in TDP-43 pathology: the disease spectrum is wider 
than ALS/FTLD and include other diseases, like NPC and myopathies. At the moment, 






Figure 18 - TDP-43 most prevalent PTMs (Buratti, 2018). 
Following many studies, the molecular events that activate aberrant TDP-43 
phosphorylation were discovered to be related to endogenous or exogenous cell stress 
conditions (Buratti, 2015; Colombrita et al., 2009). 
In Figure 19, are reported the known events in which TDP-43 phosphorylation is 
involved: in pathological cases, the main residues triggered by phosphorylation are two 
Serine residues in the C-terminal region, Ser409/Ser410. Also, phosphorylation at Ser379, 
Ser403, and Ser404 were described to correlate with disease pathology. Recently, a mass-
spectrometry analysis and in vitro studies has been performed to detect the other possible 
phosphorylation on patient’s brain samples and, as more samples are analyzed, it is 
probable that this picture will be considerably widened in the near future (Newell et al., 2018; 
Kametani et al., 2016; Neumann et al., 2009). The potentially important role of 
phosphorylation in disease is also highlighted in Figure 19 where a clear correlation may be 
observed between phosphorylation and disease-associated mutations in the TDP-43 C-
terminal region. Many mutated residues, in fact, seem to be involved either the 
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creation/disruption of Serine/Threonine residues or in the formation of a potential 
‘phosphomimic’ by the introduction of an Aspartic or Glutamic acid (Buratti, 2018). 
 
 
Figure 19 - TDP-43 aberrant phosphorylation(Buratti, 2018). 
In the future, considering the importance of phosphorylation in TDP-43 pathology, 
many targeting kinases compounds should be tested in various experimental TDP-43 
systems to check for their ability to modify TDP-43-mediated pathology. Moreover, the use 
of TDP-43 phosphorylation-specific antibodies as biomarkers of disease should improve the 













The aim of this work has been to study in detail a specific TDP-43 PTMs, namely 
phosphorylation, in two different diseases models. In particular, in the first part of the project 
I have focused on the characterization of a novel disease-associated TDP-43 mutation, 
S375G that was described in very early-onset ALS cases, that might affect the 
phosphorylation sites in the C-terminal region of this protein. In the second part of my study, 
I have focused on the involvement of TDP-43 phosphorylation in neurological defects linked 
to Niemann-Pick type C, which could become a new therapeutic target for the disease. 
Taken together, the hope is that my two aims will allow to better understand the impaired 













3.1 DNA plasmid preparation, purification, and mutagenesis 
3.1.1 Escherichia coli DH5α competent cells preparation 
E. coli DH5α strain competent cells were generated starting from frozen glycerol 
stock (1:1), stored at -80°C. DH5α glycerol was defrosted on ice, and plated on LB1-agar 
Petri dish, without antibiotics, overnight at 37°C. The day after, one colony of DH5α, was 
picked up and it was grown overnight in 10ml LB media, without antibiotics, at 37°C (pre-
inoculum). The third day, 3ml of this growth was inoculated in 100ml of LB2 media and it was 
grown at 37°C by shaking. The bacterial growing was followed by measuring the optical 
density (OD) at 590nm by using the D30 Eppendorf BioSpectometre (Eppendorf, Hamburg, 
Germany), until it reached 0.35-0.37. The suspension was centrifuged at 1000xg for 10 
minutes at 4°C. The supernatant was removed and the pellet was resuspended in 1/10 of 
the initial volume of 1% TSS3 solution. The resuspended cells were aliquoted in 1.5ml tubes, 
immediately frozen with liquid nitrogen, and then the competent cells were stored at -80°C. 
The competence of the generated DH5α cells was evaluated by transforming 100µL 
of DH5α with 0.1 ng/µl of pUC18 plasmid. The cells were plated in LB-agar Petri dish without 
antibiotics, overnight at 37°C. The day after were counted the grown colonies. The 






3.1.2 DH5α plasmid transformation 
Competent E. coli DH5α were transformed in order to amplify the amount of the 
DNA plasmid of interest, that carries the resistance for a specific antibiotic. From this 
transformation, only the colonies that have inserted the plasmid grow in the media containing 
the specific antibiotic. 
60µl of competent cells DH5α were defrosted in ice and transformed with 1µg of 
plasmid using a heat shock protocol. The cells were incubated with the plasmid in ice for 30 
minutes. At the end of this incubation, the mix was shocked at 42°C for 2 minutes. In order 
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to stop the reaction, the cells incubated with the plasmid were placed on ice for 1 minute, 
and then 60 µl of LB media was added; cells were left in a shaking incubator for 1 hour at 
37°C. At the end, the reactions were plated in LB-agar petri dish with the specific antibiotic, 
and they were incubated at 37°C overnight. 
The day after, one colony was inoculated overnight at 37°C, in 6ml (for Miniprep) or 
50ml (for Midiprep) of TB4 with the specific antibiotic. The suspension was centrifuged for 
30 minutes at 1937xg and the resulting pellets were stored at -20 °C. 
 
3.1.3 Miniprep: small scale purification of DNA plasmid 
The Miniprep technique allows to extract a small amount of plasmid from bacterial 
cultures. In this work the Wizard Plus SV Minipreps DNA purification system (Promega, 
Fitchburg, WI, USA) was used following the manufacturer’s instructions. The pellet was 
resuspended by vortexing in 250µL of resuspending solution and placed into a 1.5ml tube. 
250µL of lysis solution and 10µL of alkaline protease were added and mixed by pipetting. 
The solution was left 5 minutes at room temperature. 350µL of neutralizing solution were 
added and gently turned. The samples were centrifuged 10 minutes at 16000xg (full speed). 
The supernatant was picked up and added on the top of the Promega kit column; it was then 
centrifuged for 1 minute at 16000xg. The column was then placed in another collecting tube, 
and on the top of it 750µL of washing solution were added. The column was centrifuged for 
1 minutes at 16000xg. This step was repeated by adding 250µL of washing solution and it 
was centrifuged for 2 minutes at 16000xg. For the elution step the column was transferred 
in a 1.5 mL sterile tube and on the top of it 100µL of Nuclease-free water were added. It was 
centrifuged for 1 minute at 16000xg. Before storing it at -20°C, the amount of extracted and 
purified DNA plasmid was measured with the D30 Eppendorf BioSpectometre (Eppendorf, 
Hamburg, Germany). 
 
3.1.4 Midiprep: middle scale purification of DNA plasmid 
Middle scale preparation of DNA plasmid allows to extract medium amount of 
plasmid from total bacterial DNA. In this work, it was performed by using QIAGEN Plasmid 
Mini, Midi and Maxi kits (Qiagen, Hilden, Germany) following manufacturer’s instructions. 
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The bacterial pellet was resuspended in 4ml of P1 buffer, and 4ml of P2 buffer were added. 
It was then mixed by inverting and the resuspended pellet was left for 5 minutes at room 
temperature. After this resting time, 4ml of prechilled P3 solution were added and the tubes 
were vigorously inverted. The solution was left for 15 minutes on ice, and then it was 
centrifuged ≥20000xg for 30 minutes at 4°C. In the meantime, the QIAGEN-tip column was 
equilibrated with 4ml of QBT buffer. It was left at room temperature until the column becomes 
empty by gravity flow. After the centrifugation, the supernatant was applied to the QIAGEN-
tip. The column was washed two times with 2ml of QC buffer. The DNA was then eluted in 
a clean vessel by adding 15ml of QF buffer, and DNA was precipitated by adding 3.5ml of 
isopropanol (Honeywell, Charlotte, North Carolina, USA). The precipitated DNA was 
centrifuged at ≥15000xg for 30 minutes at 4°C. The supernatant was gently removed, and 
the pellet was washed with 2ml 70% Ethanol (Honeywell, Charlotte, North Carolina, USA). 
It was centrifuged at ≥15000xg for 30 minutes at 4°C, and the supernatant was discarded. 
The pellet was left at room temperature to air-dry it, and it was resuspended in 200µl of 
sterile water. Before storing it at -20°C, the amount of extracted and purified DNA plasmid 
was measured with the D30 Eppendorf BioSpectometre (Eppendorf, Hamburg, Germany). 
 
3.1.5 Site-directed mutagenesis technique (QuickChange) and DNA sequencing 
The site directed mutagenesis technique (QuickChange, Promega) was employed; 
this is usually used to perform insertions, deletions or mutations smaller than 10bp. 
 Two different 0.2ml tube were prepared: one for the negative control and one for 





n (for 50µl of 
reaction) 
10X Pfu buffer 1X 
Template 0,1-1ng/µl 
Deoxynucleotide (dNTP) Solution Mix 2,5mM (Rovalab, Teltow, 
Germany) 0,05mM 
Pfu enzyme  2,5U/µl 
Table 1 – QuickChange negative control reagents. 







n (for 50µl of 
reaction) 
10X Pfu buffer  1X 
Template 0,1-1ng/µl 
Oligonucleotides Sense (100ng/µl) 2,5ng/µl 
Oligonucleotides Antisense (100ng/µl) 2,5ng/µl 
Deoxynucleotide (dNTP) Solution Mix 2,5mM (Rovalab, Teltow, 
Germany) 0,05mM 
Pfu enzyme  2,5U/µl 
Table 2 – QuickChange sample reagents. 
Sterile water was used to reach the final volume and a drop of mineral oil (Sigma-
Aldrich, St. Louis, Missouri, USA) was put on the top of each sample to avoid the 
evaporation. 
As shown in table 1, in the negative control are not present the oligonucleotides in 
order to avoid the PCR reaction. 
In table 3 are reported the oligonucleotides used to insert the nucleotides mismatches. 
Name Sequence 5' → 3'  
S375G forward ATAACTCTTATGGTGGCTCTAATTC 
S375G reverse GAATTAGAGCCACCATAAGAGTTAT 
    
G376D forward ACTCTTATAGTGACTCTAATTCTGG 
G376D reverse CCAGAATTAGAGTCACTATAAGAGT 
    
N378D forward TATAGTGGCTCTGATTCTGGTGCAG 
N378D reverse CTGCACCAGAATCAGAGCCACTATA 
    
Y374X forward CTGGAAATAACTCTTAGAGTGGCTCTAATTCTGG 
Y374X reverse CCAGAATTAGAGCCCACTCTAAGAGTTATTTCCAG 
    
S375E forward ATAACTCTTATGAGGGCTCAATTC 
S375E reverse GAATTAGAGCCCTCATAAGAGTTAT 
    
S242E forward GATGATCAGATTGCGCAGGAGCTTTGTGGAGAGGACTTG  
S242E reverse CAAGTCCTCTCCACAAAGCTCCTGCGCAATCTGATCCTC 
    
S305E forward AACAATCAAGGTGAGAATATGGGTGGTGGG  
S305E reverse CCCACCACCCATATTCTCACCTTGATTGTT  











    
S404E forward GGAGGCTTTGGCTCAGAGATGGATTCTAAG  
S404E reverse CTTAGAATCCATCTCTGAGCCAAAGCCTCC  
Table 3 – Oligonucleotide sequences used for site directed mutagenesis. 
The PCR protocol was carried out using 2720 Thermal Cycler (Applied Biosystem, 
Foster City, California, USA), following the manufacture’s instruction: 
1. 95°C for 30 seconds (first denaturation); 
2. 95°C for 30 seconds; 
3. 55°C for 60 seconds; 
4. 68°C for 1minute/kb of plasmid length; 
5. 4°C. 
From step 2 to step 4 the number of cycles were set from 12 to 18, depending on 
the number of mutations that need to be inserted. When the PCR finished, 20U/µl of the 
DpnI enzyme (New England Biolabs, Ipswich, Massachusetts, USA) was added. The 
reaction was incubated for 3 hours at 37°C. The DpnI restriction enzyme cuts the wild type 
plasmid which has the methylated sites, in order to leave only the mutated (the amplified) 
one. 
From 1 to 20µl of the PCR product digested with DpnI enzyme, were then 
transformed in E. coli DH5α competent cells following the heat shock protocol5. The 
remaining reaction was stored at -20°C. 
The purified plasmid DNA was sent to GATC Biotech, a European Custom 
Sequencing Center (Eurofins Scientific, Luxembourg), to be sequenced with specific 
oligonucleotides, upstream and downstream our insert (table 4), to check if the mutation of 
interest was present and also to avoid the incidence of other sporadic mutations. 
Name Sequence 5' → 3'  
CMV 30 forward AATGTCGTAATAACCCCGCCCCGTTGACGC 
CMV 24 reverse TATTAGGACAAGGCTGGTGGGCAC 
Table 4 – Oligonucleotide sequence upstream (CMV 30 forward) and downstream (CMV 24 reverse) the insert of 
interest, used for sequencing. 
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3.2 Cell culture techniques 
3.2.1 Gene knockdown 
In this work, gene knockdown technique was applied to different cell lines by 
exploiting various reagents in order to obtain an optimal silencing efficiency. In table 5 the 
siRNA sequences of the analyzed gene are reported. Details of knockdown protocols for 
various genes are included below. 
Name Sequence 5' → 3'  
Fire-fly luciferase (siLUC) forward UAAGGCUAUGAAGAGAUAC[dT][dT] 
Fire-fly luciferase (siLUC) reverse GUAUCUCUUCAUAGCCUUA[dT][dT] 
    
TDP-43 (siTDP-43) forward GCAAAGCCAAGAUGAGCCU[dT][dT] 
TDP-43 (siTDP-43) reverse AGGCUCAUCUUGGCUUUGC[dT][dT] 
    
LCP1 (siLCP1) forward GGACAUUUAGGAACUGGAU[dT][dT] 
LCP1 (siLCP1) reverse AUCCAGUUCCUAAAUGUCC[dT][dT] 
    
EPDR1 (siEPDR1) forward GCCAGAUGGCCCAACUGGA[dT][dT] 
EPDR1 (siEPDR1) reverse UCCAGUUGGGCCAUCUGGC[dT][dT] 
    
SHANK1 (siSHANK1) forward CUCUGUAGAGGUGAUUCGA[dT][dT] 
SHANK1 (siSHANK1) reverse UCGAAUCACCUCUACAGAG[dT][dT] 
    
ITPR1 (siITPR1) forward GGAAGAACCAGGAGUAUAU[dT][dT] 
ITPR1 (siITPR1) reverse AUAUACUCCUGGUUCUUCC[dT][dT] 
Table 5 – siRNA sequences. 
 
3.2.1.1 Knockdonw in HeLa cell line 
HeLa cell are immortalized cell line derived from cervical cancer. In this work, this 
cell line was used for transient transfection experiments because they are quite amenable 
to different cellular treatments, like silencing and transfection, resulting in a high efficiency 
of the assay with a low level of non-specific death. 
HeLa cell line silencing was performed to knockdown TDP-43 gene using a siRNA 
against Fire-fly luciferase (siLUC) gene as a control. It was carried out in three days: at day 
one, 170000 HeLa cells were plated in p35 Petri dish with 1.5ml of D-MEM 6media. At day 
two and three, two rounds of silencing were performed using 3µl of Oligofectamine™ 
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Transfection Reagent (Invitrogen, Carlsbad, California, USA), following the manufacture’s 
instruction, with 80nM final concentration of siRNA (40µM) against TDP-43 and Luciferase, 
in a final volume of 1.5ml of Opti-MEM 7media. 
Other treatment followed the silencing, and after 24 hours the cells were collected 
to test splicing capability of the mutants. 
 
3.2.1.2 Knockdown in SH-Sy5Y ECACC (European Collection of Authenticated Cell 
Cultures, England) cell line 
SH-Sy5Y (ECACC, England) neuroblastoma cell line gene silencing, was performed 
to test the effect of the downregulation of some genes in relation to TDP-43 expression and 
phosphorylation. This cellular model is less prone to treatments, but it is derived from 
neuroblastoma and it can recap neuronal pathways. Considering this, Oligofectamine™ 
Transfection Reagent (Invitrogen, Carlsbad, California, USA) is too weak for this cell line, 
accordingly the knockdown was carried out using Lipofectamine RNAiMAX reagent 
(Invitrogen, Carlsbad, California, USA) following the datasheet instructions. Basically, 
800000 cells were plated and silenced at day one in p35 plates, using 9µl of Lipofectamine 
RNAiMAX reagent, 3µl of 40µM siRNA (against LCP1, EPDR1, SHANK1, ITPR1, and 
Luciferase as a control), and 150µl of Opti-MEM media, in a final volume of 1.5ml in D-
MEM:F12. One knockdown round is enough to achieve a good silencing efficacy. After 48 
hours, the cells were collected and prepared for the following tests, or to 
immunofluorescence analysis. 
 
3.2.2 Cellular transfection 
In order to obtain protein overexpression, cellular transfection with DNA plasmids 
was performed. In this work, five plasmids were used for the overexpression system: 
• pTB-CFTR_Ex9 C155T co-transfected with the pFLAG-CMV4 TDP-43 siRNA resistant 
for the add back experiments, containing the minigene with the exon 9 of the CFTR 
(Pagani et al., 2003). 
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• p-CMV4 plasmid used as a negative control in the RNA immunoprecipitation assay 
(Fig.20). 
 
Figure 20 – p-CMV4 map. 
• pFLAG-CMV4 TDP-43 siRNA resistant was used to overexpress TDP-43 wild type and 
mutated in the transient transfection experiments and for the RNA immunoprecipitation 




Figure 21 – pFLAG-CMV4 TDP-43 siRNA resistant map. 
• p5cDNA FRT/TO flag TDP-43 was used in the stable clone creation, in order to 
overexpress stably TDP-43 wild type and the mutant form in the Hek293 Flp-In T-




Figure 22 – p5cDNA FRT/TO flag TDP-43 map. 
• pOG44 was necessary for the p5cDNA FRT/TO flag TDP-43 integration during the 




Figure 23 – pOG44 plasmid map. 
 
3.2.2.1 Transfection in HeLa cell line and Hek293 Flp-In T-Rex (Life Technology, Carlsbad, 
California, USA) cell line 
For the transient transfection experiments in HeLa cells and for the stable expression 
in Hek293 Flp-In T-Rex (Life Technology, Carlsbad, California, USA), the aforementioned 
plasmids were transfected with Effectene Transfection Reagent (Qiagen, Hilden, Germany), 
following the manufacture’s instruction. Basically, the Effectene reagent is reacting in its own 
buffer (EC Buffer) with the Enhancer reagent forming micelles able to transport the DNA 
plasmid inside the cells. In table 6, the amount of reagents and plasmid are reported for the 
used plate. 













150µl 4µl 5µl 
0,5µg pTB-CFRT_Ex9 C155T 






300µl 8µl 10µl 
0,5µg pOG44 
1µg p5cDNA FRT/TO flag TDP-43 
Table 6 – Effectene transfection reagents reported according to the plate volume. 
First of all, the DNA plasmid was mixed together with the EC buffer and the 
enhancer, and this mix was left at room temperature 5 minutes. After that, the Effectene 
reagent was added and left 10 minutes at room temperature, and then the entire mix was 
administered to the cells. 
 
3.2.2.2 Transfection in SHSy5Y ECACC cell line 
The transient transfection in SHSy5Y ECACC cell line was performed for the RNA 
immunoprecipitation experiment, and it was carried out in p100 plates with the Lipofectamine 
3000 reagent (Invitrogen, Carlsbad, California, USA). Like the Effectene reagent, also the 
Lipofectamine 3000 needs an enhancer for the reaction. Basically, two mix were prepared: 
one containing 500µl of Opti-MEM and 30µl of Lipofectamine 3000; the other one composed 
by 500µl of Opti-MEM, 16µg of DNA plasmid (p-CMV4 or pFLAG-CMV4 TDP-43 siRNA 
resistant), and 32µl of p3000, the enhancer of the reaction. Then the two solutions were 
mixed together and left 10 minutes at room temperature before place it in the cell media (D-
MEM F-12, 9ml as final volume). 
 
3.2.3 Generation of Constitutive Expression Cell Lines 
The creation of a cell line that stably and constitutively expresses a gene/protein of 
interest can be a powerful tool for studying cellular processes regarding the overexpression 
of that protein or the consequences of a mutated form. 
Hek293 Flp-In T-REx (Life Technology, Carlsbad, California, USA) cell line is 
designed for rapid generation of stable clones ensuring the homogenous expression of the 
gene/protein of interest due to the presence of a Flp Recombination Target (FRT) site. 
Exploiting this technology, a tetracycline inducible cell line was created by co-transfecting 
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the plasmid p5cDNA FRT/TO flag TDP-43, together with the pOG44. As reported in Figure 
21, the p5cDNA FRT/TO plasmid is carrying the gene of interest, such as TDP-43, in frame 
with the flag tag, and it contains also the FRT homologous site to the one present in the cell 
line (Sauer, 1994). The presence of a homologous site is not enough to promote the stable 
integration of the gene of interest, and for this reason it is co-transfected with the pOG44 
vector, that contains the Flp recombinase enzyme (O’Gorman et al., 1991). Moreover, the 
expression of the protein of interest is strictly controlled and it can only be detected upon 
tetracycline induction. Indeed, the T-REx system is based on the binding of tetracycline to 
the Tet repressor, releasing the promoter and, at least, leading to the constitutive expression 
of the gene of interest (Nelson et al., 1987; Boshart et al., 1985). 
Basically, the creation of a constitutive expressing cell line takes few passages: first 
of all, 500000 Hek293 Flp-In T-REx cells were seeded in p60 plates, in D-MEM media 
containing Blasticidine S HCL (15µg/ml) (Gibco, Life Technology, Carlsbad, California, 
USA). The second day the cells were co-transfected with pOG44 and p5cDNA FRT/TO flag 
TDP-43 vectors. After 24 hours, the cells were detached with 2% trypsin-PBS8, and plated 
in p100 plates. This step will allow to select mono-clones, ensuring a proper distance 
between the single selected cells. The day after, the D-MEM media containing the selection 
for the integration, such as Hygromycin (100µg/ml) (ThermoFisher Scientific, Waltham, 
Massachusetts, USA), was added. At this point, most of the cells died, and the single formed 
clones were collected and singularly plated first in 24-well plates, and then they were moved 
in p35. At this point, the stable clones are ready to be maintained in the double selection 
(blasticidine and hygromycin) or to be tested upon Anhydrotetracycline (1µg/ml) (Sigma-
Aldrich, St. Louis, Missouri, USA) induction. In this work, the experiments on the stable 
clones were performed after 48 hours from the induction. 
 
3.2.4 Sodium arsenate treatment 
In order to induce cellular stress, the cells were treated with sodium arsenate 
following Colombrita and colleagues protocol (Colombrita et al., 2009). Briefly, the sodium 
arsenate was administrated in the cell media with the final concentration of 0.5mM, and it 
was left for 40 minutes in the incubator (37°C). After that, the media was removed, and cell 
were collected or processes for the immunofluorescence analysis. 
 




3.2.5 Toxicity study: Lactate Dehydrogenase (LDH) release toxicity assay 
The LDH release assay, is a non-radioactive toxicity analysis that quantitatively 
measures the release of lactate dehydrogenase (LDH) derived from the cell lysis. In this 
work it was used the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, 
Wisconsin, USA). 
Basically, 60000 cells were plated in 24-well plates in 500µl of media. After 24 hours, 
the cells were transfected using the Effectene method. 24, 48 and 72 hours later, the activity 
of LDH enzyme release by the cells was measured in relation to the toxicity of the treatment 
(silencing or transfection). From each well, were transferred 200µl in a tube and spun for 4 
minutes at 250xg. From the supernatant, 40µL were taken and placed in triplicate in a 96-
well plate. 40µL of substrate were added and the plate was left in dark for 30 minutes at 
room temperature. 40µL of stop solution were added in order to block the reaction. At this 
point the absorbance at 485nm was read due to the EnVision Multilabel Reader 
(PerkinElmer, Waltham, Massachusetts, USA). 
The protocol is the same for each time-laps and it needs some controls: 
• D-MEM, such as the medium culture without cells to test its background; 
• D-MEM with cells, to test the basal toxicity without transfection; 
• Maximum LDH Release Control, to test the maximum release of LDH when there is the 
apex of cell lysis. After 24 hours (and the same is for 48 and 72 hours) form the 
transfection, only in the Maximum LDH Release Control, were added 12.5µL of Lysis 
Buffer 10X (the final concentration must be 0.25X in 500µL) and incubated 40 minutes 
at 37°C. 
 
3.2.6 Mitochondria marker: MitoTracker Red CMXRos kit (ThermoFisher Scientific, 
Waltham, Massachusetts, USA) 
In order to track the mitochondria, the MitoTracker Red CMXRos kit (ThermoFisher 
Scientific, Waltham, Massachusetts, USA) was employed. This kit allows to specifically mark 
the mitochondria through a probe linked to red fluorescent dye. 250nM of MitoTracker Red 
CMXRos kit was added to the cell media, and it was left for 2 minutes. After this time, the 
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media was removed and the cells were prepared for the immunofluorescence assay. All the 
following steps were carried out in dark. 
 
3.2.7 Multipotent stem cells derived from skin biopsies differentiated in neuronal cells 
Multipotent stem cells derived from skin biopsies were cultured and differentiated by 
our collaborators at University Hospital Santa Maria della Misericordia in Udine (Italy), 
following their already published protocol (Dardis et al., 2016; Bergamin et al., 2013). 
Basically, the stem cells were enriched from patients’ skin biopsies and also from already 
established skin fibroblast cultures at early passages, through 3 steps in selective medium 
composed of 60% DMEM/40% MCDB-201 (Sigma-Aldrich, St. Louis, Missouri, USA) 
together with 1 mg/ml Linoleic Acid-BSA (Sigma-Aldrich, St. Louis, Missouri, USA); 10-9 M 
dexamethasone (Sigma-Aldrich, St. Louis, Missouri, USA); 10-4 M Ascorbic acid-2 
phosphate (Sigma-Aldrich, St. Louis, Missouri, USA); 1X Insulin transferrin-sodium selenite 
(Sigma-Aldrich, St. Louis, Missouri, USA); 2% fetal bovine serum (FBS), (STEMCELL 
Technologies, Vancouver, Canada), 10 ng/ml human PDGF-BB (Peprotech EC, London, 
UK); 10 ng/ml human EGF (Peprotech EC, London, UK) (Bergamin et al., 2013). The 
neuronal differentiation was performed by passing the cells in three different media: the first 
one, called N1, was composed by DMEM/HG with 10% FBS. After 24 hours it was replaced 
with the N2 fresh medium supplemented with 1% of B27 (Invitrogen, Carlsbad, California, 
USA), 10 ng/ml EGF (Peprotech EC, London, UK) and 20 ng/ml bFGF (Peprotech EC, 
London, UK). The cells were left for 5 days, and then they were incubated for 24/48 hours 
in N3 medium, composed by DMEM supplemented with 5 μg/ml insulin, 200 μM of 
indomethacin and 0.5 mM IBMX (all from Sigma-Aldrich, St. Louis, Missouri, USA) without 
FBS. The differentiation was determined by analyzing the expression of the neuron specific 




3.3 Propidium iodide cell cycle assay and flowcytometry analysis 
500000 Hek293 Flp-In T-REx cells were plated in p35 with the D-MEM tetracycline 
selective medium. After 48 hours from the induction, the cells were collected and 
resuspended in 300µl of ice-cold PBS and 700µl of Ethanol (Honeywell, Charlotte, North 
Carolina, USA) were added. The cells were resuspended and kept at -20°C. After few hours, 
the cells were centrifuged 5 minutes at 500xg, and the supernatant was discarded. The 
pellet was carefully resuspended with 500µl of 0.1% of Nonidet P40 (ThermoFisher 
Scientific, Waltham, Massachusetts, USA) (NP40)-PBS supplemented with of RNase 
(Sigma-Aldrich, St. Louis, Missouri, USA) (10mg/ml), and propidium iodide (5µg/ml) (Sigma-
Aldrich, St. Louis, Missouri, USA), and it was left 15 minutes in dark at room temperature. 
At this point the flowcytometry analysis was performed using FACS Calibur (Becton 
Dickinson, Franklin Lakes, New Jersey, USA). The gates were set based on physical 
parameters (side and forward scatted), and excluding/distinguishing the aggregates from 
the dividing cells (relation between area and breadth). The histogram representing the 
percentage of the events in the different phase of the cell cycle (G1, G2, S/M) was then 
created applying a third gate comparing the height and the signal intensity. In this way it was 
possible to distinguish the diploids (G1) from tetraploids (G2). The raw data were analyzed 





3.4 Immunohistochemical and immunocytochemical analysis 
3.4.1 Immunohistochemical analysis on brain region derived from S375G patient 
The immunohistochemical analysis on the S375G patient brain and spinal cord was 
carried out by our colleagues at University of Kansas School of Medicine, in Kansas City 
(USA). Basically, they harvested the brain and the spinal cord 24 hours after death. The 
right hemi-brain was sectioned fresh, while the left hemi-brain was fixed in 10% buffered 
formalin solution. For the neurohistopathological studies, they processed different 5 µm-
thick formalin-fixed sections derived from multiple areas of the central nervous system, 
including middle frontal, primary motor, cingulate, temporal, insular, parietal and occipital 
cortex, hippocampus, caudate nucleus, putamen, globus pallidus, amygdala, thalamus, 
cerebellar cortex, dentate nucleus, midbrain, pons, medulla, cervical, thoracic, lumbar, and 
sacral levels of the spinal cord. They stained the sections with hematoxylin and eosin with 
Luxol Fast Blue, and they evaluated the presence of phosphorylated and non-
phosphorylated TDP-43 using, respectively, phosphorylated TDP-43 antibody (pS409/410, 
monoclonal, Cosmo Bio, Tokyo, Japan), and non-phosphorylated TDP-43 antibody 
(polyclonal, Proteintech Group, Chicago, IL) (Newell et al., 2018). 
 
3.4.2 Immunocytochemical analysis 
primary 
antibody 
host dilution media company 
secondary 
antibody 
host dilution media company 



























































Table 7 – Immunocytochemical analysis: pramary and secondary antibodies. 
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3.4.2.1 Standard immunofluorescence assay 
According to the cellular type and the assay, on a cover glass (Corning, New York, 
USA) were plated: 
• 300000 cells for HeLa and Hek293 Flp-In T-REx; 
• 800000 cells for SH-Sy5Y ECACC. 
Because Hek293 Flp-In T-REx and SH-Sy5Y ECACC are not prone to attach to the 
cover glass surface, it has been coated with poly-L-lysine solution at a final concentration of 
0.01% (w/v) in H20 (Sigma-Aldrich, St. Louis, Missouri, USA) for 20 minutes. After this 
incubation time, the poly-L-lysine was carefully removed and the cover glass was washed 
for three times with sterile water, and it was air-dried for 1 hour under a hood. 
The immunofluorescence protocol was carried out after different assays were 
performed on the cell lines, like gene knockdown, protein overexpression, sodium arsenate 
treatment, tetracycline induction, etc. and it was carried out over two days. During day one, 
the cell media was removed and the cells were carefully washed one time with 2ml of 1X 
PBS. Then, the cells were fixed with 2ml of 3.2% para-formaldehyde (PFA) (Electron 
Microscopy Science, Hatfield, Pennsylvania, USA) in 1X PBS for 1 hours at room 
temperature. PFA was removed, and the slides were washed 3 times with 2 ml of 1X PBS. 
Cell permeabilization was performed with 2ml of 0.3%Triton (Sigma-Aldrich, St. Louis, 
Missouri, USA) in 1X PBS, left for 5 minutes in ice. Triton was removed and the slides were 
washed three times with 2ml of 1X PBS. In order to block non-specific sites, 1.5ml of 
2%BSA/1XPBS were added to the slides for 20 minutes at room temperature. The slides 
were lifted up and incubated face down with 60 µL of the primary antibody (table 7) diluted 
in 2%BSA/1XPBS, and they were left overnight at 4°C in a dark humidified chamber. The 
day after, the slides were lifted up with 1ml of 1XPBS and they were washed twice with 2ml 
of 1XPBS. The slides were incubated face down with 60µL of the secondary antibody (table 
7) diluted in 2%BSA/1XPBS for 1 hour in a dark humidified chamber. In the meantime, the 
SUPERFROST coverslip (ThermoFisher Scientific, Waltham, Massachusetts, USA) were 
cleaned with 100% isopropanol (Honeywell, Charlotte, North Carolina, USA). After the 
incubation time, the slides were picked up with 1ml of 1XPBS and they were washed twice 
with 2ml of 1X PBS. The slides were placed face down on the coverslip with 18µL of 
Vectashield with DAPI applied (Vector Laboratories Inc., Burlingame, California, USA). The 
slides were sealed with nail polish and stored in dark at 4°C.  
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The slides were analyzed with Nikon Elements AR 4.40.00 64-BIT confocal 
microscope (Nikon, Minato, Tokyo, Japan), and with LEICA epifluorescent microscope 
(Leica, Wetzlar, Germany). 
 
3.4.2.2 Immunocytochemical assay: mitochondria and Apoptosis Inducing Factor 1 (AIF1) 
protein tracking 
In order to detect the Apoptosis Inducing Factor 1 (AIF1) protein an optimized 
protocol was set-up. AIF1 is not ubiquitously expressed among various cells, but is normally 
localized in the mitochondria. The mitochondria structure was detected with the MitoTracker 
Red CMXRos kit (ThermoFisher Scientific, Waltham, Massachusetts, USA), while AIF1 
protein with mouse α- AIF1 monoclonal antibody (Invitrogen, Carlsbad, California, USA) 
(table 7). After the incubation with the MitoTracker Red CMXRos kit9, the media was 
removed and the cells, plated on the coverslip, were washed with 2ml of 1XPBS. The slides 
were fixed with 3.2% para-formaldehyde (PFA) (Electron Microscopy Science, Hatfield, 
Pennsylvania, USA) in 1XPBS for 20 minutes at room temperature, in dark. The PFA was 
removed, and the slides were washed three times with 2ml of 1XPBS. The cells were then 
permeabilized with 2ml of 0.3%Triton (Sigma-Aldrich, St. Louis, Missouri, USA) in 1XPBS, 
left for 5 minutes at room temperature in dark. Three washes with 1XPBS were followed. 
The block of non-specific sites was performed by incubating the slides with 0.1M 
glycine/PBS for few minutes. The slides were then incubated face down, in a dark humidified 
chamber, with 60µl mouse α- AIF1 monoclonal antibody (Invitrogen, Carlsbad, California, 
USA) (table 7), at 37°C overnight. The day after, the slides were recovered, washed three 
times with 1X PBS, and they were incubated with 60µl of secondary antibody (table 7). The 
incubation lasted for 30 minutes in a dark humidified chamber at 37°C. Three washes with 
1X PBS were followed. The nuclei staining was performed with bisbenzimide H33342 
trihydrochloride (Hoechst) (Sigma-Aldrich, St. Louis, Missouri, USA) (1µg/µl) diluted 1:1000 
in 2ml of 1X PBS, left for 10 seconds. The slides were washed three times with 2ml of 1X 
PBS, and then three times with 2ml of sterile water. The slides were blocked with a drop of 
Mowiol mounting medium (Sigma-Aldrich, St. Louis, Missouri, USA) and nail polish. 
 
9 Reference to 2.2.6 paragraph – 2.2.6 Mitochondria marker: MitoTracker Red CMXRos kit (ThermoFisher 
Scientific, Waltham, Massachusetts, USA). 
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The slides were analyzed with LEICA epifluorescent microscope (Leica, Wetzlar, 
Germany). 
 
3.4.2.3 Region of Interest (ROI) calculation 
For the quantitative analysis, the Regions of Interest (ROIs) were selected from the 
gray scale, monochromatic images, using Fiji win-64 (ImageJ) software, and their 
fluorescence signals were measured in arbitrary units. For each condition, the average ratio 
between the cytoplasmic and nuclear signal, was plotted in a grouped graph with standard 
deviation and number of analyzed samples using GraphPad software (GraphPad Software, 





3.5 Protein and Peptide analysis 
3.5.1 Nuclear-cytoplasmic fractionation 
For the nuclear-cytoplasmic separation, the NE-PER (Nuclear and Cytoplasmic 
Extraction Reagents) (ThermoFisher Scientific, Waltham, Massachusetts, USA) kit was 
employed. This kit allows a stepwise separation of cytoplasmic and nuclear extracts from 
mammalian cultured cells or tissue. 
1-10 × 106 cells were seeded in p100 plates, two for each condition. After the 
treatment, the cells were collected in 5ml tubes and they were centrifuged 5 minutes at 
500xg. The pellet was resuspended in 500µl of 1X PBS and the two replicates were 
combined in the same tube. The resuspended cells were transferred in 1.5ml tube and they 
were centrifuged 5 minutes at 500xg. The supernatant phase was discarded. The pellet was 
resuspended with the amount of CER I buffer necessary for the packed cell volume (table 
8). The resuspended cells were vortexed 15 seconds at maximum speed, and they were left 
10 minutes in ice. The CER II buffer was added and the sample was vortexed 5 seconds at 
maximum speed. It was left 1 minutes in ice and then it was centrifuged 5 minutes at 
16000xg. The supernatant, such as the cytoplasmic fraction, was collected and stored at -
80°C. In order to remove the remaining cytoplasmic fraction, the pellet was washed with 1X 
PBS and well resuspended. It was centrifuged 5 minutes at 16000xg. An additional step with 
CER I buffer was performed, then the sample was centrifuged at 16000xg 5 minutes, and 
the supernatant discarded. At this point the nuclear fraction can be extracted: the remaining 
pellet was resuspended with NER buffer, and it was vortex 15 seconds at maximum speed 
four times, leaving the sample at room temperature for 10 minutes between each vortex 
session. The sample was centrifuged 10 minutes at 16000xg, and the supernatant, such as 
the nuclear faction, was recovered. The nuclear fraction and the remaining pellet were 
stored at -80°C. 
Packed cell volume (µl) CER I (µl) CER II (µl) NER (µl) 
10 100 5,5 50 
20 200 11 100 
50 500 27,5 250 
100 1000 55 500 
Table 8 - NE-PER Nuclear and Cytoplasmic Extraction reagents volumes according to packed cell volume. 
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The sample concentrations were measured with Bradford (Biorad, Hercules, 
California, USA) method10, and 20µg of sample were loaded in a Sodium Dodecyl Sulphate 
(SDS) gel electrophoresis together with 4X NuPAGE LDS Sample Buffer (ThermoFisher 
Scientific, Waltham, Massachusetts, USA). 
 
3.5.2 Solubility assay: soluble-insoluble fractionation 
The solubility assay allows to detect the aggregative status of a protein by dividing 
the cell lysate in two fractions: supernatant, with soluble proteins, and pellet, containing the 
insoluble fraction. 
The cells were seeded at 70% confluency in p100 plates, and they were collected 
and resuspended in 1mL of 10X RIPA buffer (Cell Signaling Technology, Danvers, 
Massachusetts, USA). After 2 minutes at room temperature, the sample was rotated for 30 
minutes at 4°C. Following, it was centrifuged at 7000xg for 30 minutes at room temperature. 
The whole supernatant was transferred in a 1.5 ml tube, and it was sonicated in an ice-
cooled sonicating bath (BioRuptor UCD-200, Diagenode, Belgium) for 5 minutes at high 
impulse (30 seconds on, 30 seconds off), obtaining the protein subcellular fraction. The 
protein concentration was calculated with Bradford (Biorad, Hercules, California, USA) 
method. At this point, 60µg of sonicated samples were mixed with 10µL of 4X NuPAGE LDS 
Sample Buffer (ThermoFisher Scientific, Waltham, Massachusetts, USA), representing the 
input; and then it was stored at -20°C. On the other hand, 600µg of lysate were mixed with 
10X RIPA buffer (Cell Signaling Technology, Danvers, Massachusetts, USA) until they reach 
500µL of final volume, and they were transferred in Beckman polycarbonate thick wall 
Centrifuge tube (Beckman Coulter, Brea, California, USA). The sample was ultra-centrifuged 
with the OptimaTM L-90K Ultracentrifuge (Beckman Coulter, Brea, California, USA) at the 
following conditions: 
• 121968xg; 
• 1 hour; 
• 25°C; 
• acceleration: SLOW; 
• deceleration: SLOW. 
 
10 Reference to 2.5.3.3 paragraph – Bradford method 
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50µL, such as 1/10 of ultra-centrifuged sample, were added to 10µL of 4X NuPAGE 
LDS Sample Buffer (ThermoFisher Scientific, Waltham, Massachusetts, USA), representing 
the supernatant phase; and it was stored at -20°C. The left supernatant was collected in 
other tube and stored at -20°C. The remaining pellet was washed two times with 100µL of 
10X RIPA buffer (Cell Signaling Technology, Danvers, Massachusetts, USA), and then it 
was resuspended with 100µL of urea buffer11. 10µL of the resuspended pellet fraction were 
mixed with 10µL of 4X NuPAGE LDS Sample Buffer (ThermoFisher Scientific, Waltham, 
Massachusetts, USA) and it was stored at -20°C. All the collected fractions were stored at -
20°C. 
The samples, mixed with 4X NuPAGE LDS Sample Buffer (ThermoFisher Scientific, 




3.5.3 Sodium Dodecyl Sulphate (SDS) - Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
and Western Blot assay 
3.5.3.1 Sample preparation: brain tissue 
25mg of frozen formalin-fixed sections derived from multiple areas of the central 
nervous system, were cut and put in 230µl of 10X RIPA buffer (Cell Signaling Technology, 
Danvers, Massachusetts, USA), with 20µl of Protease Inhibitor Cocktail (25X) (Roche, 
Basel, Switzerland). The samples were sonicated two times in an ice-cooled sonicating bath 
(BioRuptor UCD-200, Diagenode, Belgium), 10 minutes each at high impulse (30 seconds 
on / 30 seconds off). Bradford (Biorad, Hercules, California, USA) colorimetric assay was 
performed to calculate the protein concentration, loading in the gel 10µg for each sample, 
together with 4X NuPAGE LDS Sample Buffer (ThermoFisher Scientific, Waltham, 
Massachusetts, USA). The samples were stored at -20°C. 
 
 
11 Reference to 2.8 paragraph – standard solutions 
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3.5.3.2 Sample preparation: cell lysate 
For protein detection, the samples derived from cell culture were resuspended in 
100µl of 1X PBS with 1X of Protease Inhibitor Cocktail (25X) (Roche, Basel, Switzerland). 
The cell lysate was obtained by sonicating the samples two times in an ice-cooled sonicating 
bath (BioRuptor UCD-200, Diagenode, Belgium), 5 minutes each, at high impulse (30 
seconds on, 30 seconds off). At this point, the sample concentration was detected using 
Bradford (Biorad, Hercules, California, USA) colorimetric method, and from 10 to 20µg of 
samples were loaded in the SDS-PAGE gel, together with 4X NuPAGE LDS Sample Buffer 
(ThermoFisher Scientific, Waltham, Massachusetts, USA). The samples were stored at -
20°C. 
 
3.5.3.3 Sample preparation: concentration detection using Bradford colorimetric assay  
Bradford colorimetric assay was used to detect protein concentration in order to load 
the same amount of sample for each condition. Protein assay Day Reagent Concentrated 
solution (Biorad, Hercules, California, USA) was diluted 1:5 in the cell resuspended media 
and 5µl of samples were added to a final volume of 1ml. The absorbance at 595nm was 
read with the D30 Eppendorf BioSpectometre (Eppendorf, Hamburg, Germany), and the 
final sample concentration was calculated basing on a standard curve created with scalar 
dilution of Bovine Serum Albumin (BSA) protein with a well-known starting concentration. 
 
3.5.3.4 Sample preparation: denaturation 
According to the experiment and to the protein that needs to be detected, 10 to 20µg 
of samples were loaded in the SDS-PAGE. Before loading them on the gel, the samples 
were denaturated together with 4X NuPAGE LDS Sample Buffer (ThermoFisher Scientific, 
Waltham, Massachusetts, USA) for 5 minutes at 85°C. A brief centrifuged was performed 
before loading the gel. 
 
3.5.3.5 Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) is the 
most common electrophoretic technique employed to study proteins separation based on 
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their molecular weight. Combined with the Western Blot technique, the protein of interest 
can be detected with specific antibodies. 
In this work, SDS PAGE was carried out using NuPAGE Bis-Tris 1.5mm precast 
gels (ThermoFisher Scientific, Waltham, Massachusetts, USA) 10% concentrated, and they 
were run with 1X NuPAGE MOPS SDS Running Buffer (20X) (ThermoFisher Scientific, 
Waltham, Massachusetts, USA). Gradient 4-12% NuPAGE Bis-Tris 1.5mm precast gels 
(ThermoFisher Scientific, Waltham, Massachusetts, USA) were used to better separate 
ITPR1, a high molecular weight protein. Together with the samples, Blue Protein Standard 
Broad Range (P7706S) (New England Biolabs, Ipswich, Massachusetts, USA), and 
SHARPMASS VII (EPS026500) (Euroclone S.P.A., Pero, Italy) were respectively loaded as 
molecular weight markers. 
 
3.5.3.6 Western Blot assay 
The western Blot technique provides the transfer of the separated proteins from the 
gel to a membrane in order to detect specific proteins using a couple of antibodies: the 
primary antibody, which will recognize the specific target; and the secondary antibody, that 
recognize the primary, and it is conjugated with a chemiluminescent molecule. 
In this work the transfer from the gel to the membrane was performed with Power 
Blotter–Semi-dry Transfer System (ThermoFisher Scientific, Waltham, Massachusetts, 
USA), using Power Blotter Pre-cut Membranes and Filters, Nitrocellulose (ThermoFisher 
Scientific, Waltham, Massachusetts, USA). The blot lasted for 15 minutes, using a pre-
programmed method (25V, 1.3A) for 1.5mm gels. 
To control the correct transfer, the nitrocellulose membrane was stained with Pierce 
Reversible Protein Stain Kit for Nitrocellulose Membranes (ThermoFisher Scientific, 
Waltham, Massachusetts, USA), and the image was acquired with Alliance 9.7 Western Blot 
Imaging System (UVITEC, Cambridge, UK). 
After the Pierce Reversible Protein Stain was removed, the membrane was blocked 
with 4% skimmed milk (Non-fat dry milk) or 3% Bovine Serum Albumin (BSA) (Sigma-
Aldrich, St. Louis, Missouri, USA) in 1X PBS and 0.1%/0.01% Tween-20 (Sigma-Aldrich, St. 
Louis, Missouri, USA) (PBST), depending on the antibody (table 9). The blocking lasted for 
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around 1 hour. The primary antibody was incubated overnight at 4°C, and the day after three 
washes, of 5 minutes each, with PBST were performed.  
primary 
antibody 












rabbit 1:1000 1,5%BSA/PBST 3%BSA/PBST 0,01% Cosmo Bio (Tokyo, Japan) 









α-tubulin mouse 1:10000 2%milk/PBST 4%milk/PBST 0,10% home made 
α-P84 mouse 1:1000 2%milk/PBST 4%milk/PBST 0,10% Abcam (Cambridge, UK)  





Table 9 – Primary antibodies, dilution and blocking media, and their final concentrations are reported. 
The secondary antibody (table 10) was incubated for 2 hours at room temperature. 
5 minutes washes with PBST were performed for three times. To detect the 
chemiluminescence, the membrane was incubated 2 minutes with ECL Luminata Classico 
Western HRP substrate (Merck Millipore, Burlington, MA, USA), and the images were 








α-rabbit HRP goat 1:2000 




1,5%BSA/PBST 3%BSA/PBST 0,01% 
α-mouse HRP goat 1:2000 2%milk/PBST 4%milk/PBST  0,10% 
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1,5%BSA/PBST 3%BSA/PBST 0,01% 
Table 10 - Secondary antibodies, dilution and blocking media, and their final concentrations are reported. 
Western Blot image quantification was carried out with Alliance 9.7 Western Blot 
Imaging Software (UVITEC Limited, Cambridge, UK). 
 
3.5.4 Molecular Dynamic Simulation on peptides 
The Molecular Dynamics simulations were performed by our colleagues at 
University of Castile-La Mancha, Instituto Regional de Investigación Científica Aplicada, in 
Ciudad Real (Spain). Briefly, the molecular dynamic simulation was based on the structure 
of NNSYSG peptide, that was modeled using ZipperDB database. They generated the 
S375G and S375E variants from the NNSYSG peptide taking advantage of PyMOL 
software. In all simulations, all the described structures were solved using TIP3P water 
molecules, pre-equilibrated at 1 atm and 300 K, and then individually submitted to 50-ns 




3.6 Nucleic acids analysis 
3.6.1 DNA extraction and genetic analysis of the S375G patient’s brain tissue 
This was performed by our colleagues at University of Kansas School of Medicine, 
in Kansas City (USA). Genomic DNA was extracted from frozen brain tissue and the 
products were treated with ExoSAP-IT (USB, Cleveland, OH, USA). They were then 
amplified using the DTCS Quick Start Kit (Beckman Coulter, Fullerton, CA, USA), and the 
products were analyzed on a CEQ 8000 GeXP Genetic Analysis System (Beckman Coulter). 
A comparison between the resulting DNA with the known sequences 
(www.ncib.nlm.nih.gov) was carried out (Newell et al., 2018; Murrell et al., 1991). 
 
3.6.2 RNA extraction 
3.6.2.1 Sample preparation: brain tissue 
In order to preserve the RNA tissue from freeze/thaw cycles, the frozen formalin-
fixed sections derived from multiple areas of the central nervous system, were kept on dry 
ice; less than 50mg was cut. 700µl of QIAzol Lysis Reagent (Qiagen, Hilden, Germany) were 
added and the sample were homogenized with Utra-Turax T25 basic (IKA-WERKE GMBH 
& CO, Staufen im Breisgau, Germany) for 7 seconds. At this point, the RNA was extracted 
from the tissue. 
 
3.6.2.2 Sample preparation: cell lysate 
For RNA extraction, the cells were collected and the medium was removed. In order 
to better remove the culture medium, the cell pellet was washed with 1X PBS and 
centrifuged 5 minutes at 500xg, discarding the supernatant. At this point the cells were 
resuspended in 700µl of QIAzol Lysis Reagent (Qiagen, Hilden, Germany) and the RNA 
extraction was performed. 
 
3.6.2.3 miRNeasy Mini Kit (Qiagen, Hilden, Germany) 
In this work the RNA was extracted with the miRNeasy Mini Kit (Qiagen, Hilden, 
Germany), with some adjustment from the manufacturer’s instructions. Briefly, the samples 
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(homogenized tissue or cell lysate) were transferred in 5PRIME Phase Lock gel tubes 
(Quantabio, Beverly, Massachusetts, USA), pre-centrifuged at 1500xg for 30 seconds, and 
the sample was left 5 minutes at room temperature. 140µl of chloroform (Sigma-Aldrich, St. 
Louis, Missouri, USA) were added; to mix the two reagents, the 5PRIME Phase Lock gel 
tubes were vigorously shaken and the samples were left 5 minutes at room temperature. To 
separate the phases and obtaining the aqueous/RNA supernatant, the samples were 
centrifuged at 4°C 10 minutes at 16000xg. The 5PRIME Phase Lock gel interposes the gel 
phase between the aqueous phase and the Qiazol one, containing what needs to be 
discarded. In this way, the supernatant is cleaner and it was easily collected and moved it 
into another collection tube where 1.5 volume of 100%ethanol (Honeywell, Charlotte, North 
Carolina, USA) was added. After this first separation, the RNA was extracted with the 
miRNeasy kit (Qiagen, Hilden, Germany): 700µl of the sample were pipetted on the RNeasy 
Mini spin column and it was centrifuge at 8000xg for 15 seconds at room temperature. The 
flow through was discarded. This step was repeated for the remaining sample. 700µl of 
buffer RWT were added upon the column and it was centrifuged at 8000xg for 15 seconds 
at room temperature. Again, the flow through was discarded. Two steps of washing with 
500µl of Buffer RPE were performed, centrifuging the samples at 8000xg for 15 seconds at 
room temperature. The second centrifuge step was performed for 2 minutes at 8000xg, in 
order to remove any ethanol residues. The column was placed on 2ml another collection 
tube and it was centrifuged at full speed for 1 minute to eliminate RPE buffer residuals. At 
this point the RNA was eluted: the column was put on 1.5ml collection tube and 30µl of 
RNase-free water were added. The column was centrifuged at 8000xg for 1 minute and the 
RNA was eluted. 
RNA concentration and the purification level were measured with D30 Eppendorf 
BioSpectometre (Eppendorf, Hamburg, Germany), using the Eppendorf µCuvette G1.0 
(Eppendorf, Hamburg, Germany). The absorbance at 260nm was measured together with 
the ratio between the absorbance at 260/280nm (protein contamination) and at 260/230nm 
(reagents contamination). 
 
3.6.3 Reverse transcription reaction: complementary DNA (cDNA) preparation 
Starting from the extracted RNA, the complementary DNA (cDNA) was 
retrotranscribed with Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) 
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(Invitrogen, Carlsbad, California, USA), in the presence of random primers (Sigma-Aldrich, 
St. Louis, Missouri, USA). Two mixes were prepared: the first one containing the RNA and 
the random primers with the concentrations reported in table 11. To reach the final volume 
of 20µl, sterile water was added. With this composition, the first mix was chilled at 85°C for 
5 minutes, it was briefly centrifuged, and the sample was cooled in ice for 1 minute.  
reagent final concentration (final volume=20µl) 
RNA 50ng/µl 
random primers (100ng/ml) (Sigma-
Aldrich, St. Louis, Missouri, USA) 1ng/µl 
Table 11 – cDNA preparation: mix 1 containing random primers and RNA. 
At this point, 20µl of the second mix were added. The second mix composition is 
reported in table 12. 
reagent final concentration (final volume=20µl) 
5X M-MLV buffer 2X 
Dithiothreitol (DTT) (100mM) Invitrogen (Carlsbad, 
California, USA) 20mM 
Deoxynucleotide (dNTP) Solution Mix (2,5mM) 
(Rovalab, Teltow, Germany) 0,5mM 
M-MLV (200 U/µl) 5 U/µl 
Table 12 - cDNA preparation: mix 2 containing reverse transcription reaction reagents. 
M-MLV reaction was carried out at 37°C for 1-2 hours. The samples were then 
stored at -20°C before using for gene expression or splicing analysis. 
 
3.6.4 Pre-mRNA splicing analysis 
Pre-mRNA splicing analysis was carried out by using the Polymerase Chain 
Reaction (PCR) technique, and it was performed in 50µl of final reaction volume, composed 
by 3µl of cDNA (or sterile water for the negative control sample) and 37µl of PCR mix (table 
13). To reach the final volume, sterile water was added. 
reagent 




10X ThermoPol reaction Buffer (New England Biolabs, Ipswich, 
Massachusetts, USA) 1X 
Deoxynucleotide (dNTP) Solution Mix (2,5mM) (Rovalab, Teltow, 
Germany) 0,2mM 
Primer forward (100ng/µl) 3ng/µl 
Primer reverse (100ng/µl) 3ng/µl 
Taq Biolabs 5 U/µl (New England Biolabs, Ipswich, 
Massachusetts, USA) 0,02U/µl 
Table 13 – PCR reaction mix. 
The pre-mRNA splicing was tested for the cDNA extracted from the HeLa cells, 
knockdown for TDP-43 and transient transfected with mutant TDP-43 plasmids (addback 
experiment); and from the stable cell lines expressing constitutively TDP-43 mutated forms. 
For the HeLa cells, the pre-mRNA splicing assay was performed on the minigene containing 
the exon 9 of the CFTR gene. The minigene technique allows to recreate a splicing event 
when transfected into cells. In this work, the minigene system is carrying CFTR exon 9 and 
a small portion of intron 8 and 9, including a mutation in a splicing enhancer element in order 
to obtain a 50/50 ratio of exon inclusion/skipping. On the other hand, the pre-mRNA splicing 
analysis was carried out using one of the best characterize endogenous TDP-43 target, such 
as DNA Polymerase Delta Interacting Protein 3 (POLDIP3) gene. In table 14 are reported 
the primer sequences. 
Name Sequence 5' → 3'    
α2-3 CAACTTCAAGCTCCTAAGCCACTGC 
pTB-CFTR_Ex9 C155T  
BRA2 CACCAGGAAGTTCCTTAAATCA 




Table 14 – Pre-mRNA splicing primer sequences. 
The two experiments required different PCR protocols in order to optimize the 
fragments amplification (table 15) and they were carried out with MiniAmp Plus Thermal 
Cycler (Applied Biosystem, Foster City, California, USA). 
target temperature time cycles 
pTB-CFTR_Ex9 C155T  
95°C 2 minutes   
94°C 45 seconds 
35 54°C 45 seconds 
72°C 45 seconds 
72°C 10 minutes   
4°C ∞   
        
POLDIP3 94°C 2 minutes   
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94°C 30 seconds 
35 56°C 1 minute 
72°C 45 seconds 
72°C 10 minutes   
4°C ∞   
Tabella 15 – Pre-mRNA splicing protocols. 
PCR products were then run with the QIAxcel DNA Screening Kit (Qiagen, Hilden, 
Germany), providing the separation of the nucleic acid basing on size, using a capillary filled 
with a precast agarose gel. Before starting, the cartridge was immerged in the QX Wash 
Buffer (Qiagen, Hilden, Germany) for 20 minutes. For the running, the instrument requires 
two different markers to separate correctly the samples and to identify the size of the DNA 
fragments: the QX Alignment Marker 15 bp/3 kb (Qiagen, Hilden, Germany), that establishes 
the range in which identify the bands; and the QX DNA Size Marker 50 bp – 1.5 kb (Qiagen, 
Hilden, Germany), that gives information about the fragment size. The size marker must be 
included in the range of the alignment marker and together create the reference marker. At 
this point, 15µl of sample were loaded in the QX 0.2 ml 12-Tube Strips (Qiagen, Hilden, 
Germany) and the run was performed using the AM420 method. The QIAxcel DNA 
Screening Kit (Qiagen, Hilden, Germany) output generate a gel image, for the qualitative 
analysis, and the electropherogram, by which it is possible to quantify the signal intensity 
calculating the Area Percentage of the electropherogram peaks. The obtained data were 
then analyzed with GraphPad software (GraphPad Software, La Jolla California, USA). 
 
3.6.5 Gene expression analysis: real time quantitative PCR (qPCR) 
Gene expression analysis was performed on cDNA prepared from: 
• S375G patient brain samples in order to study TDP-43 expression, using the 
hippocampal TDP-43 as the internal control. To normalize the results, Glyceraldehyde-
3-phosphate Dehydrogenase (GAPDH) was used as the housekeeping gene;  
• Multipotent stem cells, differentiated in neurons derived from NPC patients and healthy 
controls, in order to validate RNA sequencing data, especially regarding the following 
genes: Cadherin 18 (CDH18), Doublecortin Like Kinase 1 (DCLK1), DEP Domain 
Containing MTOR Interacting Protein (DEPTOR), Cell Adhesion Associated, Oncogene 
Regulated (CDON), Leucine Rich Repeat Containing G Protein-Coupled Receptor 4 
(LGR4), Inositol 1,4,5-Trisphosphate Receptor Type 1 (ITPR1), Lymphocyte Cytosolic 
Protein 1 (LCP1), SH3 And Multiple Ankyrin Repeat Domains 1 (SHANK1), Ependymin 
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Related 1 (EPDR1), and TDP-43. Glyceraldehyde-3-phosphate Dehydrogenase 
(GAPDH) and Hypoxanthine Posphoribosyltransferase 1 (HPRT1) expression was not 
changing between the NPC and healthy samples, so they were employed as 
housekeeping genes to normalize the results. 
• On SH-Sy5Y to test the expression of ITPR1, LCP1, SHANK1, and EPDR1 genes, upon 
their knockout, using the siLUC as the relative control. Glyceraldehyde-3-phosphate 
Dehydrogenase (GAPDH) and Hypoxanthine Posphoribosyltransferase 1 (HPRT1) 
were used as housekeeping genes. 
• And on SH-Sy5Y cell line after the RNA immunoprecipitation experiment, in order to test 
the following gene enrichment: Cadherin 18 (CDH18), Doublecortin Like Kinase 1 
(DCLK1), DEP Domain Containing MTOR Interacting Protein (DEPTOR), Cell Adhesion 
Associated, Oncogene Regulated (CDON), Leucine Rich Repeat Containing G Protein-
Coupled Receptor 4 (LGR4), Inositol 1,4,5-Trisphosphate Receptor Type 1 (ITPR1), 
Lymphocyte Cytosolic Protein 1 (LCP1), SH3 And Multiple Ankyrin Repeat Domains 1 
(SHANK1), and Ependymin Related 1 (EPDR1). Glyceraldehyde-3-phosphate 
Dehydrogenase (GAPDH) was used as housekeeping gene. 
In table 16 are reported the forward and reverse primer sequences employed for the 
gene expression analysis. The primer sequence was generated using PrimerBank online 
tool (https://pga.mgh.harvard.edu/primerbank/). All the forward and reverse primer 
sequences are placed on different exons; therefore, no DNase treatment was performed in 
order to eliminate possible presence of genomic DNA. 
Name Sequence 5' → 3'    
GAPDH forward CGCTCTCTGCTCCTCCTGTT 
Housekeeping genes 
GAPDH reverse CCATGGTGTCTGAGCGATG 
    
HPRT1 forward TGACACTGGCAAAACAATGCA 
HPRT1 reverse GGTCCTTTTCACCAGCAAGCT 
      
      
TDP-43 forward ATCTGGTGGTATGTTGTCAACTATCC 
Target genes 
TDP-43 reverse GAACTTCTCCAAAGGTACTAAAATACTC 
    
LCP1 forward GATCAGTGTCCGATGAGGAAATG 
LCP1 reverse CCAGATCACCTGTAGCCATCA 
    
EPDR1 forward GTCCAGGAGTGGTCGGACA 
EPDR1 reverse ACACCGAGGGGTCTTTAATACC 
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SHANK1 forward TGGACCCCAATTACCATGACT 
SHANK1 reverse CATGCGGCCTTATGCAGTG 
    
ITPR forward GCGGAGGGATCGACAAATGG 
ITPR1_rev TGGGACATAGCTTAAAGAGGCA 
    
CDON forward AAAGCTGAGGTGCGCTATAAAA 
CDON reverse AAGAAGGACGACTCACAAGGA 
    
LGR4 forward TCGAGGGCTGAGTGCTTTG 
LGR4 reverse ATGCCGTAACTGAACAAGTCC  
    
DCLK1 forward GCTGATTTGACCCGAACTCTG 
DCLK1 reverse AGCCACATACATAACTCTCTCCT 
    
DEPTOR forward TTAGCAGACCGGGGCATTATT  
DEPTOR reverse GAAGGTGCCGTCATCCTTTCT 
    
CDH18 forward CAAAAGGGGATGGGTATGGATC 
CHD18 reverse CCCGTGGTATCGTCAATGATAAA 
 
Table 16 – Quantitative Real Time PCR primer sequences. 
For the first two, the gene expression was validated using CFX96 Touch Real-Time 
PCR Detection System (Biorad, Hercules, California, USA); for the SH-Sy5Y knockdown 
and RNA immunoprecipitation experiments, the QuantStudio 5 Real-Time PCR System, 96-
well, 0.1 mL block (ThermoFisher Scientific, Waltham, Massachusetts, USA) machine was 
used. The two instruments required different protocols and different master mix reagent, the 
best for the quantitative Real Time PCR run optimization (table 17). 
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Table 17 – Quantitative Real Time PCR protocols and related master mix reagents. 
To perform the gene expression analysis, 4µl of diluted cDNA (1:5 for the S375G 
patient brain regions; 1:10 for the other two experiments, in sterile water) was added to 6µl 
of reagents mix, composed by: the master mix reagent containing the DNA polymerase, the 
dNTPs mix, and the DNA intercalant agent that binds the nucleic acid in a non-specific 
manner, emitting a proportional fluorescence to the quantity of the amplified DNA; the 
forward and reverse primer, specific for the target gene or the housekeeping gene; and 
sterile water to reach the final volume (table 18). 
Reagent Final Concentration  
Master mix reagent  
SYBR Green Master Mix (Biorad, Hercules, California, USA)  
or  
PowerUp™ SYBR™ Green Master Mix (Applyed Biosystems, Foster 
City, California, USA) 
diluted 1:2 
Primer forward (20µM) 0,5µM 
Primer reverse (20µM) 0,5µM 
Table 18 – Quantitative Real Time PCR reagents mix. 
The expression levels were calculated exploiting different methods: 
• For the S375G patients TDP-43 expression, the comparative CT methods was applied 
(Schmittgen and Livak, 2008), in which the 2-ΔΔCT was calculated. This method was 
applied in order to correct the higher heterogeneity between the different cut sections. 
Also, for the RNA immunoprecipitated samples was used this method, in order to better 
calculate the mRNA enrichment. 
• For the RNA sequencing validation on multipotent stem cells, differentiated in neurons, 
derived from NPC patients and healthy controls, the homogeneity between the different 
samples was higher (supported also by the RNA sequencing results), therefore, CFX 
Maestro Software for CFX Real-Time PCR Instruments (Biorad, Hercules, California, 
USA) was exploited where the normalized expression (ΔΔCq) was calculated by the 
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software. The obtained data were then plotted in grouped table with GraphPad software 
(GraphPad Software, La Jolla California, USA). 
• For the SH-Sy5Y knockdown samples, the Thermo Fisher Connect Cloud, Relative 
Quantification qPCR app (ThermoFisher Scientific, Waltham, Massachusetts, USA) was 
employed for the relative quantification (Rq) analysis. As per company suggestion, the 
software is merging together the independent experiments and it analyzes the Rq, upon 
indication of the normalization parameters, such as the housekeeping genes and the 
internal reference control (siLUC for example). The data were then plotted in a grouped 
table with GraphPad software (GraphPad Software, La Jolla California, USA). 
 
3.6.6 RNA sequencing analysis of differentially expressed genes 
Before sending the samples for the RNA sequencing analysis, the RNA extracted 
from multipotent stem cells, differentiated in neurons, derived from NPC patients and healthy 
controls were tested for their quality in terms of purification and integrity, using the QIAxcel 
RNA QC Kit v2.0 (Qiagen, Hilden, Germany). The instrument provides the RNA Integrity 
Score (RIS) that indicate the quality of the extracted RNA basing on the quality of 28s and 
18s ribosomal RNA. This number should be higher than 7 for the RNA sequencing protocol 
optimization. According to this, 1µl of RNA sample were diluted 1:1 with the QX Denaturation 
buffer (Qiagen, Hilden, Germany) and the sample was denaturated at 70°C for 2 minutes. 
The same treatment was performed also for the QX RNA size marker 200-6000bp (Qiagen, 
Hilden, Germany). 8µl of QX Dilution buffer (Qiagen, Hilden, Germany) were added, and the 
sample was run in the QX RNA cartridge (Qiagen, Hilden, Germany) together with the QX 
RNA size marker 200-6000bp (Qiagen, Hilden, Germany) and the QX RNA size marker 
15bp (Qiagen, Hilden, Germany). 5µg of the samples with RIS number higher than 7 and 
with optimal values of 260/280 and 260/230 absorbance, were send to Novogene 
(Novogene Co., Ltd, Beijing, China) for the sequencing.  
Novogene (Novogene Co., Ltd, Beijing, China) performed both the sequences as 
well as the bioinformatic analysis concerning the clusterization, gene ontology (GO) analysis 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. 
Basically, they purified the mRNA from total RNA using poly T oligos attached to 
magnetic beads, and then it was randomly fragmented using a fragmentation buffer. 
Secondly, a NEB library was prepared (Fig.24): the first strand cDNA was synthesized using 
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random hexamer primers and M-MuLV Reverse Transcriptase (RNase H-). The second 
strand cDNA synthesis was performed using DNA Polymerase I and RNase H. After 
adenylation of 3' ends of DNA fragments, NEBNext Adaptor (New England Biolabs, Ipswich, 
Massachusetts, USA) with hairpin loop structure was ligated to prepare for hybridization. 
The cDNA fragments were then purified with AMPure XP system (Beckman Coulter, 
Beverly, USA) of 150~200 bp in length and they were obtained by PCR amplification. 
 
Figure 24 – NEB library proposed by Novogene. 
A library quality assessment was performed and the samples were sequenced using 
the Illumina technology (Fig.25). We chose a paired end analysis improving the capability 
to identify the relative positions of various reads in the genome. In contrast with the single 
end analysis that reads the fragment from one end to the other, the paired end performs to 
reading steps in the opposite directions. As a depth of coverage, we decided for 60mln of 
reads per samples, in order to cover also low-abundant transcripts. We choose these stricter 
parameters for two reasons: first of all, the samples that we sequenced were directly derived 
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from humans (skin biopsies) and this depth of coverage with the paired end analysis allowed 
us to flatten the difference between the same samples’ category (controls or patients), and 
to detect small perturbations between the patients and the controls. Moreover, as I will later 
explain, we were interested in the differentially expressed genes, but this type of analysis 
could allow us to go in deeper and also to check for the different alternative splicing events. 
 
Figure 25 – Illumina sequencing scheme (Novogene report). 
The bioinformatic analysis was carried out: a quality check of the sequencing was 
performed by calculating the error rate distribution, such as the sequencing error rate related 
to the base quality values of the Illumina machine; and the GC content to detect potential 
AT/GC separation, such as when G and C, A and T are not in an equal rate. 
Also, the obtained data were filtered by removing the reads containing adaptors; 
eliminating the reads containing a number of bases that cannot be determinate higher than 
10%; and they cut out the reads with a quality score of over 50% bases of the read is less 
than 5.  Finally, the clean reads were mapped on the reference genome: Novogene aligned 
the paired-end clean reads to the reference genome using STAR (v2.5) software, that 
exploits the method of Maximal Mappable Prefix (MMP) generating a precise mapping result 
for junction reads. 
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In order to quantify the gene expression level, HTSeq v0.6.1 software was used to 
count the read numbers mapped for each gene, and the Reads Per Kilobase of exon model 
per Million mapped reads (FPKM) was calculated basing on the length of the gene and the 
reads count mapped to this gene. 
Differential expression analysis was performed with edgeR package, and the 
threshold of differential expression genes was applied: 0.7<Fold Change (FC)>1.3 and p-
value adjusted (pAdj)<0.05. 
The Venn diagrams were prepared using the function Venn Diagram in R based on 
the gene list for different group. 
Cluster Analysis of differential expression genes was used to estimate expression 
pattern of differential expression genes under different experimental conditions. Hierarchical 
clustering analysis was carried out with the log10(FPKM+1) of union differential expression 
genes of all comparison groups under different experimental conditions. 
Gene Ontology (GO) enrichment analysis of differentially expressed genes was 
implemented by the cluster Profiler R package, in which gene length bias was corrected. 
GO terms with corrected pAdj less than 0.05 were considered significantly enriched by 
differential expressed genes. 
KEGG database is a resource for understanding high-level functions and utilities of 
the biological system (http://www.genome.jp/kegg/). Novogene used cluster Profiler R 
package to test the statistical enrichment of differential expression genes in KEGG 
pathways. KEGG terms with padj < 0.05 are significant enrichment. 
 
3.6.7 RNA immunoprecipitation (RNA-IP) assay 
2800000 SH-Sy5Y ECACC cells were seed in p100 plate (three plates for the target 
plasmid and one for the negative control) with D-MEM:F12 cultured medium, in order to 
achieve 70-80% of confluence the day after. The second day, the cells were transfected with 
pFLAG-CMV4 TDP-43 vector using Lipofectamine 3000 reagent 12 (Invitrogen, Carlsbad, 
California, USA), and with p-CMV4 plasmid without the insert. After 24 hours, the cells were 
collected: the three plates transfected with the target protein were merged and the samples 
 
12 Reference to 2.2.2.2 paragraph – SHSy5Y ECACC cell line 
93 
 
were centrifuged at 500xg for 5 minutes. The supernatant was discarded and the cells were 
resuspended in: 3ml of ice-cold 1X PBS for the negative control, and 6ml of ice-cold 1X 
PBS, for the target protein that were then divided it in 3 tubes (2ml per tube). The samples 
were centrifuged at 500xg for 5 minutes and the supernatant was discarded. One pellet from 
the target transfection and the pellet transfected with the negative control, were tested with 
SDS-PAGE and Western Blot techniques in order to check the transfection efficacy. 
The last two pellets, transfected with the target protein underwent to the RNA 
immunoprecipitation assay, performed with the Imprint® RNA Immunoprecipitation Kit 
(Sigma-Aldrich, St. Louis, Missouri, USA). 
The first step is the cell lysis: in this work, the Mild Lysis Buffer (Sigma-Aldrich, St. 
Louis, Missouri, USA) was employed because it is a nonionic detergent and it leaves the 
nuclei intact. According to the cell number, different volumes of reagents were used for the 
pellet resuspension, following table 19: 
Reagent 
Volume for 0.5-




Mild Lysis Buffer (Sigma-Aldrich, St. Louis, Missouri, 
USA)  
or  
Harsh Lysis Buffer (Sigma-Aldrich, St. Louis, Missouri, 
USA) 
100µl 200µl 
Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, 
Missouri, USA) 1µl 2µl 
Dithiothreitol (DTT) (100mM) Invitrogen (Carlsbad, 
California, USA) 0,05µl 0,1µl 
Ribonuclease Inhibitor 40U/µl (Sigma-Aldrich, St. Louis, 
Missouri, USA) 0,4µl 0,8µl 
Table 19 – RNA-IP lysis reagents volume, according to cell range. 
After the resuspension, the samples were incubated in ice for 15 minutes, and then 
they were centrifuged 10 minutes at 16000xg at 4°C. The supernatant was collected and its 
volume was measured. 10% of the lysate supernatant was removed, corresponding to the 
“10% Input”, such as the initial control. The “10% Input” was stored at -80°C. 
In the meantime, the preparation of the Protein A Magnetic Beads (Sigma-Aldrich, 
St. Louis, Missouri, USA) was performed: the magnetic beads were resuspended and 
0.02ml were quickly transferred to each 1.5ml microcentrifuge tube. 0.1ml of RIP Wash 
Buffer (Sigma-Aldrich, St. Louis, Missouri, USA) were added, and the beads were briefly 
vortexed. The tubes were placed on a magnetic separator support in order to ease the 
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supernatant separation and the beads collection. This wash step was repeated. At this point 
the beads are ready for the bridging antibody pre-binding. The tubes were briefly centrifuged 
and the beads were resuspended in 0.1 ml of RIP Wash Buffer (Sigma-Aldrich, St. Louis, 
Missouri, USA) and they were transferred in 0,5ml microcentrifuge tubes. 1µl of bridging 
antibody (in this work IgG from mouse serum, Sigma-Aldrich, St. Louis, Missouri, USA), and 
they were incubated for 30 minutes at room temperature in rotation. After this time, the tubes 
were briefly centrifuged and the magnetic beads-bridging antibody complex were 
resuspended in 0.1 ml of RIP Wash Buffer (Sigma-Aldrich, St. Louis, Missouri, USA) and 
they were transferred in 1.5ml tubes. The tubes were placed on a magnetic separator and 
the supernatant was discarded. 0.5ml of RIP Wash Buffer (Sigma-Aldrich, St. Louis, 
Missouri, USA) were added, and the samples were briefly vortexed. Again, the supernatant 
was discarded employing the magnetic support. This wash step was repeated one again. At 
this point the specific antibody prebinding was performed: one was hybridizing with the 
target-specific antibody, such as α-flag M2, Invitrogen, Carlsbad, California, USA; and the 
other with a negative control antibody, such as the Anti-mouse IgG antibody produced in 
rabbit (Sigma-Aldrich, St. Louis, Missouri, USA). The beads were resuspended in 0.1 mL of 
RIP Wash Buffer (Sigma-Aldrich, St. Louis, Missouri, USA) and they transferred in 0,5ml 
microcentrifuge tubes. 5µl of specific antibody were added, and the beads were incubated 
in rotation for 30’ at room temperature. Then, the tubes were briefly centrifuged. The 
magnetic beads-specific antibody complex was resuspended with 0.1 ml of RIP Wash Buffer 
(Sigma-Aldrich, St. Louis, Missouri, USA) and they were transfer in 1.5ml tubes. The 
supernatant was discarded. 0.5ml of RIP Wash Buffer (Sigma-Aldrich, St. Louis, Missouri, 
USA) were added and the samples were briefly vortexed and centrifuged. The supernatant 
was discarded and the wash step was repeated with 0.2ml of RIP Wash Buffer (Sigma-
Aldrich, St. Louis, Missouri, USA). Now the beads are ready for the immunoprecipitation 
step. In table 20, are reported the employed volumes for the IP-buffer preparation, with the 
final volume of 0.5ml for each sample. 
Reagent Volume 
RIP Wash Buffer (Sigma-Aldrich, St. Louis, Missouri, USA) 1000µl 
Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, Missouri, USA) 10µl 
Ribonuclease Inhibitor 40U/µl (Sigma-Aldrich, St. Louis, Missouri, 
USA) 4µl 
Table 20 – IP-buffer preparation mix. 
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The supernatant was discarded from the beads and the immunoprecipitation 
reaction was set and it was composed by prebound beads, the IP Buffer, and the cell lysate. 
The mix was incubated overnight in rotation at 4°C. The day after, the samples were briefly 
centrifuged and 10% of the supernatant was removed, representing the Negative Control 
Reaction supernatant, called “Negative Control RNA-IP Input”. This sample was stored at -
80°C. The remaining supernatant was discarded and washing step followed. 1ml of RIP 
Wash Buffer (Sigma-Aldrich, St. Louis, Missouri, USA) was added and the samples were 
gently vortexed. The RNA-IP reaction was transferred into a fresh 1.5ml tube that was 
quickly spun down and the supernatant was removed. This wash step was repeated five 
times, moving the sample always in a fresh 1.5ml tube. After this, the samples were 
resuspended in 200µl of RIP Wash Buffer (Sigma-Aldrich, St. Louis, Missouri, USA). The 
10% Input sample was recovered and lift up to a final volume of 200µl using RIP Wash 
Buffer (Sigma-Aldrich, St. Louis, Missouri, USA). 
At this point, enriched RNA was purificated: 500µl of EuroGold Trifast (Euroclone, 
Milan, Italy) were added and the samples were incubated for 5 minutes at room temperature. 
100µl of chloroform (Sigma-Aldrich, St. Louis, Missouri, USA) were summed and the 
samples were incubated for 3 minutes at room temperature. They were then centrifuged at 
16000xg for 15 minutes at 4°C. The supernatant aqueous phase was collected and it was 
placed in a new collection tube. 6µl of RNA-glycogen 5mg/ml (final concentration 0.05µg/µl) 
(ThermoFisher Scientific, Waltham, Massachusetts, USA), 60µl of 5M ammonium acetate 
(Honeywell, Charlotte, North Carolina, USA), and 600µl of isopropanol (Honeywell, 
Charlotte, North Carolina, USA) were added. The samples were vortexed and then they 
were stored at -80°C for 2-3h, to precipitate the RNA. After the -80°C incubation, the 
samples were thawed in ice, and then they were centrifuged at 16000xg for 10 minutes at 
4°C. The supernatant was removed and the pellet was washed once with 500µl of 80% 
ethanol (Honeywell, Charlotte, North Carolina, USA) solution. They were centrifuged at 
16000xg for 10 minutes at 4°C, the supernatant was discarded and the pellet was air-dried 
at 37°C for few minutes. Then it was resuspended in 20µl sterile water and the 
concentration, the purification, and the quality of the extracted RNA was tested with D30 
Eppendorf BioSpectometre (Eppendorf, Hamburg, Germany), using the Eppendorf µCuvette 
G1.0 (Eppendorf, Hamburg, Germany). The absorbance at 260nm was measured together 
with the ratio between the absorbance at 260/280nm (protein contamination) and at 
260/230nm (reagents contamination). The samples were stored at -80°C. 
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The RNA extracted was retrotranscribed in cDNA and the abundance of possible 




3.7 Statistical analysis 
The statistical analysis was performed on three independent experiments, using 
GraphPad software (GraphPad Software, La Jolla California, USA). An unpaired t-test or a 
multiple comparison Anova test with Bonferroni correction were carried out, and the 





3.8 Standard solutions 
- 1X PBS (Phosphate Buffer Saline): 137mM NaCl; 2.7mM KCl; 10mM Na2HPO4; 
2mM KH2PO4 pH 7.4 
- LB medium (Luria-Bertani medium): 10g Bacto Tryptone; 5g Yest Extract; 10g 
NaCl pH 7.5  per liter. 
- TB: (Terrific Broth) medium: 1.2% peptone, 2.4% yeast extract, 72 mM K2HPO4, 
17 mM KH2PO4 and 0.4% glycerol 
- 1X TSS (Transformation & Storage Solution): 10%PEG 4000 (5g); 35mM MgCl2 
(1.75 mL MgCl2 1M); 35mL LB (without antibiotics); lead to pH 6.5 with HCl 0.5M; 
filter with 0.22µm membrane; DMSO 2.5ml  50ml. 
- D-MEM: Dulbecco’s Modified Eagle’s Medium, composed by High Glucose 1X; L-
glutamine; Phenol Red; Sodium Pyruvate (Gibco, Life Technology, Carlsbad, 
California, USA). With fetal bovine serum 10% (Life Technology, Carlsbad, 
California, USA) and antibiotic antimycotic solution 1% (Sigma-Aldrich, St. Louis, 
Missouri, USA). 
- Opti-MEM: Opti-MEM® Reduced-Serum Medium with L-glutamine and Phenol 
Red (Gibco, Life Technology, Carlsbad, California, USA). Lack of Bovine Serum. 
- D-MEM:F12: Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham, 
composed by L-glutamine, 15mM HEPES, and sodium bicarbonate, liquid, sterile-
filtered (Sigma-Aldrich, St. Louis, Missouri, USA). With fetal bovine serum 15% 
(Life Technology, Carlsbad, California, USA) and antibiotic antimycotic solution 1% 












4.1 Characterization of a TDP-43 mutation in an ALS case that might 
affect phosphorylation sites in the C-terminal region of this protein. 
4.1.1 Clinical case: TDP-43 S375G unpublished variant associated with ALS 
This work started with the study of a clinical case in collaboration with the 
Department of Pathology & Laboratory Medicine of the University of Kansas School of 
Medicine (Kansas City, USA). In this work, Kathy Newell and Dino Ghetti studied the brain 
and spinal cord of a 26-year-old woman clinically diagnosed with ALS at the very early age 
of 22, and with a history ALS in distant relatives. Neuropathologic evaluation showed the 
upper and lower motor neuron impairment with an immunoreaction for the phosphorylated 
TDP-43 (Fig.26) (Newell et al., 2018).  
 
Figure 26 – phosphoTDP-43 density and distribution of immunoreactive neurons and glia of the motor cortex. In panel A 
are shown the upper cortical layers; in panel B the lower cortical levels. 10X original magnification  (Newell et al., 2018). 
Figure in collaboration with Kathy Newell. 
An autopsy was carried out on samples derived from central nervous system frozen 
regions: the primary motor cortex, neurons, and glial cells were positively stained for 




Figure 27 – phosphoTDP-43 density and distribution of different brain areas. 40X original magnification (Newell et al., 
2018). Figure in collaboration with Kathy Newell. 
Due to the availability of a high number of brain regions from this ALS case, it was 
possible to compare the expression levels of phosphoTDP-43 (pTDP-43) in neuronal and 
glia cells, and compare it with the total TDP-43 mRNA expression in order to determine 
whether phosphoTDP-43 (pTDP-43) levels were correlated with total TDP-43 expression 
levels (Newell et al., 2018). Figure 28 shows that results revealed prominent differences in 
the analyzed brain regions. As expected, most of the pTDP-43 staining was concentrated in 
the areas affected by the disease, such as the primary motor cortex and the spinal cord, 
while pTDP-43 absence was detected in the hippocampus (Fig.28A). In contrast, however, 
TDP-43 total mRNA expression levels were constant in all the analyzed regions with few 
exceptions, especially in the dentate nucleus (cerebellum) where expression levels were 
considerably higher than in the other tissues (Fig.28B). These mRNA expression data were 
confirmed by Western blot analysis (Fig.28C) (Newell et al., 2018). Taken together, the 
analysis revealed that there is no simple correlation between the amount of pTDP-43 and 
total TDP-43 expression in different brain regions (Newell et al., 2018). In fact, this 
observation suggests that altered phosphorylation is not a simple reflection of relative TDP-
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43 expression levels in different brain regions but may be a consequence of pathological 
mechanisms that are active only in selected brain areas. 
 
Figure 28 – pTDP-43 amount in glial and neuronal cells versus total TDP-43 expressed. A) in this panel the pTDP-43 
amount, found in different brain regions of the patient, was plotted in a graph. B) total TDP-43 expressed levels were 
detected by quantitative Real Time PCR on different brain regions derived from the patient. Hippocampus was used as 
the internal standard sample. C) western blot analysis on brain regions stained with α-TDP43 antibody. Tubulin was used 
as standard loading control (Newell et al., 2018). 
At the time of discovery, it was still unclear the reason for this early onset of disease. 
In fact, little information was available about her siblings that could help identify disease 
segregation and familiarity. Both parents were healthy and without clinical history of 
neurological disorders. The same was for the patient’s older kin, even though some 
occurrence of ALS in distant relatives was documented. In particular, one of the parent’s 
cousin was diagnosed with ALS after the fifth decades of age. Also, the other parent had a 
great uncle who was clinically diagnosed with ALS. Moreover, a grandmother was reported 
to have died with late onset Alzheimer. Nonetheless, there was no direct link to disease, 
leaving uncertain the classification of this patient as a familial or sporadic case. 
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To start addressing this issue at the molecular level, we performed a molecular 
genetic analysis on extracted DNA from frozen brain tissue. No C9ORF72 expansion, or 
sequence alterations in SOD1, ANG, FIG4, and FUS genes were reported; however, a novel 
S375G (AGT>GGT) change was identified in a mutational hot-spot of TDP-43 gene, the C-
terminal region of the protein (Fig.29) (Newell et al., 2018). 
 
Figure 29 – TDP-43 S375G variant located in the CTD (Newell et al., 2018). Figure in collaboration with by Kathy Newell. 
Bioinformatics analyses performed on this mutation using well known prediction 
programs such as SIFT, PolyPhen-2, SNAP, etc. failed to predict an effect of this mutation 
on protein functionality. However, considering the severity of the disease in this patient, I 
tested the effects of this variant on TDP-43 localization, pre-mRNA splicing activity, and 
toxicity, in parallel with the effects on neighboring disease-associated mutations. Moreover, 
this variant was hypothesized to potentially affect a potential post-translational modification 
site, with the deletion of a phosphorylation site in the C-terminal domain of TDP-43 protein 
(Kametani et al., 2016; Hasegawa et al., 2008). 
 
4.1.2 Characterization of S375G variant and of the adjacent G376D, N378D, and Y374X 
TDP-43 disease-associated mutants. 
4.1.2.1 Splicing capability 
As described in the introduction section, TDP-43 is mostly known for its involvement 
in splicing. Based on this, I first tested the splicing capability of S375G comparing it to 
neighboring disease-associated mutations (G376D, N378D, and Y374X). The splicing assay 
was performed in transient transfected HeLa cells with a minigene containing the CFTR 
exon 9 (C155T) following the knockdown of the endogenous TDP-43. As reported in Figure 
30, the change in CFTR exon 9 inclusion was measured following the addition of flagged-
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siRNA-resistant wild type TDP-43 (WT), an RNA-binding impaired mutant (F4L) as a 
negative control, and the mutant variants. After a reverse transcriptase PCR amplification, 
using minigene-specific primers, the levels of CFTR exon 9 inclusion (Ex 9+) were measured 
by QIAxcel DNA Screening Kit (Fig.30A). The results from three biological triplicates are 
reported in Figure 30B: no difference in splicing pattern between the WT and S375G variant, 
as in the other neighboring mutations, was detected (Newell et al., 2018). In panel C of 
Figure 30 is reported the silencing and transfection efficiency, measured by Western Blot.  
 
Figure 30 – Addback splicing assay. A)  QIAxcel capillary electrophoresis gel image reporting CFTR exon 9 splicing for 
the WT, F4L; and the TDP-43 mutant forms. The samples were silenced with the siLUC, as a control (-), and with the 
siTDP-43 (+). In all the samples the minigene containing the CFTR exon 9 was transfected, while the different TDP-43 
forms were added-back in all the TDP-43 silenced samples, except for the negative control (Add-back “–“). B) Statistical 
quantification analysis of the gel image. Unpaired t-test was performed using GraphPad software (GraphPad Software, 
La Jolla California, USA); C) Western blot image stained with α-TDP-43 antibody detecting flag-tag TDP-43 (the 
transfected one) and endogenous silenced TDP-43. Tubulin was used as internal standard loading control. The “+” 
sample is showing the endogenous TDP-43 in the siLUC sample; the “-“ is still the endogenous silenced TDP-43. The 
WT, F4L, S375G, G378D, and N378D represent the added-back TDP-43 forms in the TDP-43 knockdown cells (Newell 
et al., 2018).  
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The same experiment was repeated for TDP-43 Y374X nonsense mutation, in order 
to understand if the lack of the last 33 residues was somehow impairing the splicing 
capability of the protein. As shown in Figure 31, the Y374X stop-codon mutation was still 
preserving the splicing capability of the protein compared to the WT (Fig.31A and 31B). As 
above, a Western blot analysis was performed to confirm the silencing and the transfection. 
As shown in Figure 31C, the flag-TDP-43 Y374X band was not present. The reason for this 
apparent discrepancy is that it is not possible to distinguish the endogenous TDP-43 from 
the flagged one because this truncated mutant protein migrates together with the unflagged 
endogenous protein (Newell et al., 2018). 
 
Figure 31 – TDP-43 Y374X nonsense mutation addback analysis. A) QIAxcel capillary electrophoresis gel image 
reporting CFTR exon 9 splicing. The samples were silenced with the siLUC, as a control (-), and with the siTDP-43 (+). In 
all the samples the minigene containing the CFTR exon 9 was transfected, while the different TDP-43 forms were added-
back in all the TDP-43 silenced samples, except for the negative control. B) Statistical quantification analysis of the gel 
image. Unpaired t-test was performed GraphPad software (GraphPad Software, La Jolla California, USA); C) Western 
blot image stained with α-TDP-43 antibody detecting the transfected flag-TDP-43 and silenced endogenous TDP-43. 
Tubulin was used as internal standard. The “-“ sample represent the negative control silenced with the siLUC and the 
total endogenous TDP-43 was stained. In the “+” sample the cells were just silenced for TDP-43 without any added-back 
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form, and the silenced TDP-43 was stained. The WT, F4L, and Y374X shows the TDP-43 staining of the added-back 
forms in the cells silenced for the endogenous TDP-43. (Newell et al., 2018).  
 
4.1.2.2 Immunolocalization analysis 
Secondly, I investigated whether the S375G substitution could affect the intracellular 
localization of TDP-43 in comparison with the wild-type protein or with respect to TDP-43 
localization occurring in disease-associated mutations G376D and N378D, that had been 
previously described by other authors but not well characterized (Newell et al., 2018; Buratti, 
2015). 
The subcellular distribution of all the TDP-43 mutants was investigated in transient 
transfected HeLa cell line with flag-tagged TDP-43 forms mentioned also in the previous 
paragraph. As reported in Figure 32, the wild-type TDP-43 was predominantly nuclear, with 
a lower abundance in the cytoplasm, due to the continuous shuttling of the protein between 
the two compartments. While the G376D and N378D substitutions did not significantly affect 
the distribution of TDP-43, which remained prominently nuclear, in the S375G variant the 
distribution of TDP-43 was significantly more nuclear than in any other mutants (Fig.32A 
and 32B). This result was also confirmed by the western blot separation of the nuclear-




Figure 32 – pFlagSiRTDP-43 subcellular localization. A) Immunofluorescence localization: flag-TDP-43 WT, S375G, 
G376D, N378D transfected plasmids were detected with α-flag antibody, nuclei were stained with DAPI. B) Quantification 
of nuclear-cytoplasmic staining intensity for WT flag-TDP-43, S375G, G376D and N378D was performed by measuring 
the Region of Interest (ROI). Unpaired t-test was performed using GraphPad software (GraphPad Software, La Jolla 
California, USA). C) Nucleus-cytoplasmic (N/C) distribution of transiently transfected HeLa cells with flag-tagged wild-
type TDP-43 and flag-tagged S375G mutant. The detection of p84 and tubulin was performed as control for 
nuclear/cytoplasmic contamination of the two fractions (Newell et al., 2018).  
The intracellular localization was also performed for the Y374X mutant. As reported 
in Figure 33, however, the absence of the last 33 residues did not impair the sub-cellular 
localization compared to WT (Newell et al., 2018). 
 
Figure 33 – Y374X TDP-43 mutant immunolocalization (Newell et al., 2018). 
 
4.1.2.3 TDP-43 mutants’ cellular toxicity: LDH release assay 
According to the previous results, I therefore examined whether the S375G, G376D, 
N378D, and Y374X substitutions could increase cellular toxicity in relation with WT protein. 
To perform this analysis, HeLa cells were transiently transfected with the flagged TDP-43 
vectors: after 24-, 48-, and 72-hours lactate dehydrogenase (LDH) levels were measured. 
The LDH levels in the cell medium levels after 24 hours did not show any difference between 
the mutants, compared to cells transfected with wild-type TDP-43 (Fig.34A). On the other 
hand, the expression of the S375G caused a strong significant cytotoxicity after 48 hours 
that was similar to that of the other mutants (Fig.34B) and even stronger than some if we 
consider that the N378D mutant showed a toxic effect only after 72 hours (Fig.34C). In all 
transfected cells, Western blot analysis against total TDP-43 showed that the flagged wild-
type and mutant proteins were expressed at similar levels after 48 hours post-transfection 
(Fig.34D) (Newell et al., 2018). Taken together, these results have suggested that, although 
TDP-43 functional properties in the regulation of pre-mRNA splicing were not affected, this 
mutation still had the ability to alter the nuclear cytoplasmic balance of this protein. As a 
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consequence, this novel S375G mutation displayed a toxicity that was comparable, and 
even somewhat greater, than neighboring disease-associated mutations. What these results 
did not explain, however, was the reason why this change could affect the cellular 
distribution of TDP-43.  
 
Figure 34 - LDH release. Levels were measured 24 hours (A), 48 hours (B) and 72 hours (C) after cells transfection with 
the specific constructs. Multiple comparison one-way Anova test with Bonferroni’s correction was performed using 
GraphPad software (GraphPad Software, La Jolla California, USA). D) Western blot analysis of flagged TDP-43 protein 
expression after 48 hours to show comparable expression of all mutants in our cell line. Tubulin was used as the internal 
standard loading control (Newell et al., 2018). 
 
4.1.2.4 Functional effects of mimicking post-translational phosphorylation at the S375 
position 
According to the literature (Kametani et al., 2016; Hasegawa et al., 2008), the most 
likely hypothesis for the change introduced by this replacement of Serine with a Glycine 
could be to prevent the eventual phosphorylation of position 375. Therefore, to test the 
potential effects of phosphorylation at this position I prepared a phosphomimic mutant of 
TDP-43 where the Serine in position 375 was mutated with a Glutamic Acid (S375E) (Newell 
et al., 2018).  
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I then tested both the immunolocalization and the splicing capability of this 
phosphomimic mutant protein like we did for the S375G mutation (Fig.35). 
Immunohistochemistry analysis showed that, contrarily to the S375G variant, the localization 
of the S375E mutant protein is not confined to the nucleus, but is present in the cytoplasm 
(Fig.35A), while the toxicity of the S375E substitution was comparable to that of the S375G 
variant. I also performed an add-back experiment to correlate the mislocalization with CFTR 
exon 9 splicing and I observed no alteration emerged comparing to the wild-type TDP-43 
(Fig.35C). These results suggested that the amount of TDP-43 persisting in the nucleus is 
sufficient to drive correct splicing of the transfected minigene (within the limits of this 
transient assay) (Newell et al., 2018). 
 
Figure 35 - S375E phosphomimic analysis. A) Immunofluorescence analysis of the pFlagSiRTDP-43 S375G and S375E. 
The mutant TDP-43 was detected with an α-flag antibody (red) and the nuclei were stained with DAPI. A ROI 
quantification is also reported showing a significant difference between the amount of protein present in the cytoplasm of 
the transfected cells. Unpaired t-test was performed using GraphPad software (GraphPad Software, La Jolla California, 
USA). B) LDH release assay. Multiple comparison one-way Anova test with Bonferroni’s correction was performed using 
GraphPad software (GraphPad Software, La Jolla California, USA). C) Add-back assay performed with QIAxcel, testing 
exon 9 splicing with the S375E phosphomimic. A western blot analysis was performed to detect the efficiency of 
Silencing and the presence of the transfected protein (Newell et al., 2018). 
Neurodegenerative disorders are characterized by cellular stress and looking at the 
effects of these two mutations on the cellular distribution of TDP-43 it was therefore 
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interesting to see what happens if the cells are stressed following transfection. For this 
reason, I induced cell stress by treating HeLa cells with sodium arsenate (Colombrita et al., 
2009). Upon this condition,  the S375E phosphomimic showed an even stronger cytoplasmic 
localization than WT, whereas the S375G seemed to remain mostly unaffected and still 
predominantly localized in the nucleus (Fig.36) (Newell et al., 2018). 
 
Figure 36 - S375G and S375E immunolocalization under sodium arsenate stress conditions. In red are detected the 
transfected WT, S375G and S375E using an α-flag antibody. The nuclei are stained with DAPI (blue). Unpaired t-test 
was performed using GraphPad software (GraphPad Software, La Jolla California, USA) (Newell et al., 2018) 
 
4.1.2.5 Analysis of the effects of other sites in TDP-43 CTD that have been shown to 
undergo phosphorylation 
Based on these results, I therefore decided to consider the neighboring residues to 
S375 in the C-terminal tail of the protein in order to understand if the capability to balance 
the nuclear-cytoplasmic amount of the protein was specific  for the region or whether this 
ability to affect TDP-43 localization was a specific property of the 375 residue (Newell et al., 
2018). 
In particular, to perform this analysis I decided to consider two paper from 
Hasegawa’s group that were published in 2008 and 2016 and analyzed the potential 
phosphorylation sites in vitro and in two patients in vivo by mass spectrometry (Kametani et 
al., 2016; Hasegawa et al., 2008).  
Following the literature (Buratti, 2015), I therefore combined the potential 






In vivo ALS P1 In vivo ALS P2 Mutations References 
S 2 √ X X     
Y 4 √ X X     
T 25 √ X X     
T 88 √ X X     
S 91 √ X X     
S 92 √ X X     
T 116 √ X X     
S 183 √ X X     
S 242 √ √ √     
S 273 √ X X     
S 292 √ X √ S292N (Zou et al., 2012; Xiong et al., 2010) 
S 305 √ √ √     
S 317 X √ √     
S 332 X X √ S332N (Corrado et al., 2009) 
S 333 X X √     
S 342 √ X X     
S 347 √ X X     
S 350 √ X X     
S 369 √ X X     
S 373 X X √     
S 375 √ √ √ S375G   
S 377 √ X X     
S 379 √ X √ S379C / S379P 
(Chiang et al., 2012; 
Ticozzi et al., 2011; 
Corrado et al., 2009) 
S 387 √ √ √ S387delinsTNP (Solski et al., 2012) 
S 389 √ √ √     
S 393 √ √ √ S393L 
(Praline et al., 2012; 
Origone et al., 2010; 
Corrado et al., 2009) 
S 395 √ √ √     
S 403 √ √ X     
S 404 √ √ √     
S 407 √ X √     
S 408 √ X √     
S 410 √ X √     
Table 21 - TDP-43 potential phosphorylation sites and disease-associated mutations already described in literature. 
Using these criteria, I was therefore able to extend my functional analyses to other 
sites (highlighted in yellow in table 21) localized in TDP-43 C-terminal domain. As a 
consequence, I then prepared four different phosphomimic flag-tag, siRNA-resistant, TDP-
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43 plasmid, mutating the Serine (S) residue with a Glutamic acid (E) (Newell et al., 2018).  
As shown in Figure 37, all of these changes were single residue mutation except for the 
S387-95E which included four different mutation sites (S387, S389, S393, S395) because 
the Serine residues of interest were one next to the other (Newell et al., 2018).  
 
Figure 37 - TDP-43 phosphomimic analyzed residues. 
In Figure 38 are reported the immunohistochemical data obtained on transfected 
HeLa cells of all these mutants. After analyzing the immunofluorescence images (Fig.38A) 
and from the ROI graph (Fig.38B), it is clear that the only phosphomimic plasmid able to 
reproduce the phenotype of the S375E was the S387-95E, composed by four different 
mutated sites (Newell et al., 2018). Taken together, these results have suggested that the 
capability to balance TDP-43 amount in the nucleus or in the cytoplasm can be specifically 
connected to S375 potential phosphorylation and that phosphorylation events in the S375 
surrounding region could contribute in controlling TDP-43 intracellular redistribution (Newell 





Figure 38 - TDP-43 CTD phosphomimic analysis. A) immunolocalization of TDP-43 phosphomimic in CTD. B) Nuclear-
cytoplasmic localization derived from ROI analysis. Multiple comparison one-way Anova test with Bonferroni’s correction 
was performed using GraphPad software (GraphPad Software, La Jolla California, USA) (Newell et al., 2018). 
 
4.1.2.6 Molecular dynamic (MD) simulation: propensity of β-sheet formation in TDP-43 371-
376 CTD segment upon S375G and phosphomimic S375E substitutions 
The results obtained by the phosphomimic mutants could not explain, however, why 
a phosphorylation event at this site is capable of affecting TDP-43 localization. To further 
characterize this point, we decided to focus on the structural integrity of the WT sequence 
comparing to the S375G and the S375E mutants. In particular, I decided to focus on inter-
molecular interactions that might be occurring in this region between different TDP-43 
molecules.  Thanks to the help of our collaborators in Spain (University of Castile-La 
Mancha, Instituto Regional de Investigación Científica Aplicada (IRICA), Ciudad Real, 
Spain; and Instituto de Química Física “Rocasolano”, Consejo Superior de Investigaciones 
Científicas, Madrid, Spain) we performed structural investigations of the TDP-43 C-terminal 
region that includes the S375 residue. First of all, three segments of the CTD containing the 
residue of interest were selected for peptide synthesis: N371-NSYSG376 for the WT protein; 
N371-NSYGG376 for the variant S375G; and N371-NSYEG376 for the phosphomimic S375E. 
On these segments, our collaborators performed molecular dynamic simulations and, as 
shown in Figure 39, a measure was obtained at three different time points (Fig.39A) as well 
as the Cα–Cα intra-β-sheet distances were measured throughout the course of the 
simulations (Fig.39B). As shown in this figure, both WT and S375G exhibited a high 
structural stability, which we interpret as the ability to S375G to maintain inter-protein 
contacts similar to those of the WT sequence. On the other hand, S375E showed an 
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instability assembly due to the presence of strong electrostatic repulsions which are 
promoting structure dissociation (Newell et al., 2018). 
Taken together, these results suggest that phosphorylation of S375 might mediate a key 
aspect of TDP-43 assembly and nuclear localization, meaning that the lack of S375 
phosphorylation induced by the mutation can promote TDP-43 self-association and 
therefore its nuclear retention (Newell et al., 2018). 
 
 
Figure 39 – Molecular dynamic simulation analysis. A) The molecular dynamic trajectories were followed at 0 (green) and 
after 50ns (blue). From the overlap of the starting and the finishing sequence, the WT and the S375G remained 
assembled during the simulation time; instead, the phosphomimic S375E variant was disassembled. B) Cα- Cα inter-β-
strands and intra-β-sheet measurements. Each of these distances was calculated at each data point of the simulation, 
and they were all averaged and plotted (lower part of the panel). Whereas WT and S375G inter-strand distances 
remained constant over time (blue and violet curves),  S375E (red) increased as a result of disassembly (Newell et al., 




4.1.3 Creation of a stable cell line expressing S375G and S375E 
The problem with transient transfections is that the relatively low efficiency of cells 
producing the transfected protein and time limitations do not allow to fully appreciate what 
could be the functional differences introduced by these mutations. Therefore, based on the 
results obtained with the transient transfection experiments, I decided to create a stable 
cellular model in which the flag-tag, siRNA resistant S375G and the S375E variants could 
be expressed constantly following induction (together with a stable cell line stably expressing 
wild-type TDP-43). 
As discussed in detail in the Material and Methods section, I prepared these different stable 
clones in the Hek293 Flp-In T-REx (Life Technology, Carlsbad, California, USA) cell line 
where the exogenous protein can be inducible expressed upon addition of Tetracycline to 
the cell media. Following these results, I tested all the prepared stable clones for what 
concern the protein expression. As reported in Figure 40, in the flag-tag siRNA resistant 
TDP-43 WT two clones, on five prepared, did not work; all the clones prepared for the S375G 
have a good expression; all the S375E clones are fine, with the exception for the S375E1 
clone 2 in which the expression is also present in the Tet off (-) sample, maybe due to small 





Figure 40 - Western blot analysis of all the stable clones prepared. The stable protein was detected with α-flag antibody 
and the tubulin was used as internal standard: the band under the tubulin is the flag antibody because they are detected 
with the same secondary antibody. 
Subsequential selection of the positive clones, WT1-Clone1, S375G2-Clone1, and 
S375E2-Clone4 were employed for all the following assays due to their similar expression 
levels. Figure 41 show the levels of protein expression at 24, 48 and 72 hours after induction 
for all three cell lines expressing TDP-43, WT, S375G and S375E. As shown in this figure, 
expression remained stable for all three different time laps and for all further experiments I 




Figure 41 - Western blot analysis testing stable clones’ expression at three different time points: 24, 48 and 72 hours. 
The expression of the stable allele upon tetracycline induction, was detected with α-flag antibody, specific for the 
recognition of the stable protein only. Tubulin was used as a standard loading control. 
First of all, although in transient transfection I observed no effects of these mutations 
on TDP-43 splicing ability, I decided to look again at the splicing capability of the various 
TDP-43s in the stable clones (because of its presumably greatest sensitivity). In particular, 
because all cells are producing the exogenous protein upon induction, there was no reason 
to transfect the CFTR minigene as a reporter system. Instead, I decided to look at POLDIP3 
as an endogenous target gene in all three cell lines (Fig.42). The reason this gene was 
chosen is because it is one of the most well characterized endogenous targets from the 
point of view of TDP-43 splicing properties. In this gene, in fact, the inclusion of exon 3 is 
completely dependent on the binding of TDP-43 to a UG-rich region downstream from the 
5’ss (Fiesel et al., 2012). In normal conditions, TDP-43 splicing activity results in about 80% 
of exon 3 inclusion and approximately 20% of exon 3 exclusion. As shown in Figure 42, the 
S375G mutant and the S375E phosphomimic cell lines were behaving exactly as the WT in 
terms of keeping the same inclusion/exclusion ratio of exon 3, thus confirming the previous 
results obtained with the CFTR exon 9 mini gene in the transient transfection experiments 




Figure 42 - POLDIP3 gene splicing analysis. A) Qiaxcel capillary electrophoresis gel image. B) Statistical analysis of 
POLDIP3 exon 3 inclusion performed with multiple comparison one-way Anova test with Bonferroni’s correction using 
GraphPad software (GraphPad Software, La Jolla California, USA). 
The availability of these stable clones also represented a powerful tool that could 
clarify some involved processes bypassing the limits of a transient transfection. For 
example, they are suitable to examine eventual alterations in TDP-43 autoregulation levels 
or the presence of this protein in the soluble or insoluble fraction. 
Following this idea, I first studied the behavior of the S375G mutant and the S375E 
phosphomimic in the autoregulation process of endogenous TDP-43. As previously 
mentioned in the Introduction, TDP-43 is able to bind to a specific region in the 3’UTR of its 
pre-mRNA and trigger the skipping of intron 7 that contains one of the major polyadenylation 
sites of its mRNA (pA1). Loss of this polyadenylation site forces the use of another 
suboptimal polyA site (pA2) and this leads to nuclear retention and degradation of the 
transcript. In fact, one of the first observations we did when expressing TDP-43 in a stable 
manner was that the induced exogenous protein was capable of “switching-off” expression 
of the endogenous gene (Budini and Buratti, 2011). It was therefore interesting to see if the 
S375G and S375E clones were capable of downregulating the endogenous gene as well as 
the WT TDP-43 protein. As shown in Figure 43, however, all stable alleles were able to 
inhibit expression of the endogenous TDP-43 in a similar manner and no statistical 
differences were reported in autoregulation activity of the mutated TDP-43 form comparing 




Figure 43 - S375G and S375E stable alleles autoregulation on the endogenous TDP-43. A) Western Blot analysis 
performed against total TDP-43. Tubulin was used as a loading control. B) Statistical analysis of endogenous TDP-43 
expression levels performed with multiple comparison one-way Anova test with Bonferroni’s correction using GraphPad 
software (GraphPad Software, La Jolla California, USA). 
As autoregulation was not impaired, I then decided to study the presence of the 
mutated proteins in the soluble/insoluble fraction, something that would have been difficult 
to study in transient transfection because of the lower expression. However, all the stable 
proteins were present both in the soluble as in the insoluble fraction even though they are 
mainly soluble (Fig.44). Therefore, also for the solubility assay, no significant differences 
could be reported for S375G and S375E compared to WT. 
 
Figure 44 - Western Blot analysis of the solubility assay performed on the stable clones. The membranes were stained 
against the total TDP-43. I used the Pierce Reversible Protein Stain Kit for Nitrocellulose Membranes (ThermoFisher 
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Scientific, Waltham, Massachusetts, USA) as a loading control. Please note that the Pierce Reversible staining kit does 
not allow any quantification. 
The same assay was also repeated upon sodium arsenate treatment, in order to 
check if the protein solubility could have changed in cell stress conditions. However, upon 
induced stress conditions, both mutated forms of TDP-43 remained mainly soluble as the 
WT (Fig.45). 
 
Figure 45 - Western Blot solubility assay of the stable clones upon arsenate treatment. The membranes were stained 
against the total TDP-43. I performed the Pierce Reversible Protein Stain Kit for Nitrocellulose Membranes 
(ThermoFisher Scientific, Waltham, Massachusetts, USA) as a loading control. Please note that the Pierce Reversible 
staining kit does not allow any quantification. 
Considering that the autoregulation and the solubility assay yielded negative results, 
I then tested the stable clones for the immunolocalization of the mutants in order to see if 
there were more distinguishing features that were not observed in previous transient 
expression experiments  (Newell et al., 2018). Interestingly, as shown in Figure 46, I noticed 
that in the S375G and the S375E stable clones there seemed to be an abundance of nuclei 
with a non-canonical shape (highlighted with white circle in Figure 46), similar to 
dividing/apoptotic cells. This outcome had not been noticed in the transient transfection 
experiments probably because in transient transfections only a minority of cells were actually 
transfected by the plasmids. Importantly, this difference was particularly present for the 
phosphomimic S375E mutant that showed a higher number of non-canonical nuclear shape 




Figure 46 – Stable clones immunolocalization analysis. A) Immunofluorescence images are reported for all the stable 
clones with and without tetracycline induction. Here I reported the merged images between the nuclei (DAPI channel in 
blue); and the Alexa-Fluor 594 (red) detecting the anti-flag TDP-43 (such as the stable alleles expression). B) Statistical 
analysis of the percentage of non-canonical nuclear shape was performed with unpaired t-test using GraphPad software 
(GraphPad Software, La Jolla California, USA). 
This immunolocalization experiment was also performed upon induced cell stress 
conditions, after treating the stable clones with sodium arsenate. In stress conditions, the 
number of non-canonical nuclear shape increased in both the mutant forms (S375G around 
20%, and S375E around 30%), but it was constantly higher for the phosphomimic variant 
(Fig.47). 
 
Figure 47 - Immunolocalization analysis upon sodium arsenate treatment. A) Immunofluorescence images are reported 
for all the stable clones with and without tetracycline induction. Here I reported the merged images between the DAPI 
channel (blue), staining the nuclei; and the Alexa-Fluor 594 (red) detecting the anti-flag TDP-43 (such as the stable 
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alleles expression). B) Statistical analysis of the percentage of non-canonical nuclear shape was performed with 
unpaired t-test using GraphPad software (GraphPad Software, La Jolla California, USA). 
Following this interesting result, I tested if the S375G mutation and especially if the 
phosphomimic mutant S375E could affect cell cycle. 
It is in fact known through the literature that TDP-43 is involved in mRNA stability of 
Cyclin Dependent Kinase (CdK6), an important regulator of cell cycle progression in the 
restriction point (Youhna M Ayala et al., 2008). To investigate the possible impairment of the 
cell cycle and Cdk6 involvement in this observed increase of cell division I performed a 
Western Blot analysis against Cdk6. As shown in Figure 48, however, no differences were 
reported between the WT and the S375G/S375E mutant forms in Cdk6 expression levels. 
 
Figure 48 - Western Blot against CdK6. Tubulin was performed as a standard loading control. 
In parallel, in order to check if this observation was due to an impairment of the cell 
cycle, a flow cytometry (FACS) analysis was performed using propidium iodide staining. As 
shown in Figure 49, the G2 phase in the S375G and S375E seemed to be significantly 




Figure 49 - Cell cycle analysis performed with flow cytometry and propidium iodide staining. In the upper part of the 
figure the cell cycle trend was reported for each clone stably expressing the TDP-43 form (WT, S375G, S375E mutants). 
The results were plotted in a grouped table and a multiple comparison one-way Anova test was performed using 
GraphPad software (GraphPad Software, La Jolla California, USA) 
In literature, TDP-43 ctd fragmentation was already described to be linked with 
caspase apoptosis, but is still unknown if the caspases are activated intrinsically as a result 
of aberrant TDP-43 aggregation or other mechanisms are occurring (Yamashita et al., 
2014).. Moreover, it is already known that TDP-43 neurotoxicity can trigger the mitochondria 
pathway (Braun et al., 2011). In particular the Apoptosis-inducing factor 1 (AIF1), a 
mitochondrial protein, was described to be consistently involved in neuronal death (Shibata 
et al., 2009; Krantic et al., 2007; Candé et al., 2002). Upon a lethal signal or a strong and 
persistent cellular stress, AIF1 protein translocate, via the cytosol, to the nucleus where it 
binds to DNA and provokes caspase-independent chromatin condensation (Candé et al., 
2002). For this reason, AIF1 protein expression and sub-cellular localization was studied. 
As shown in Figure 50 panel A, AIF1 expression was found to be increased in the S375G 
and in the S375E expressing clones. This data was also consistent with the 
immunolocalization experiment in which the AIF1 expression was more robust in the 
mutants. Moreover, also AIF1 sub-cellular localization was changing, following the 
hypothesis of mitochondria-related apoptosis. As reported in Figure 50B, in the WT 
expressing clone, AIF1 (in green) mainly localized with the mitochondria signal (red). This 
co-localization was also present for the S375G mutant, even if a part of the protein was 
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present also in the nucleus. This result was even more evident for the phosphomimic S375E 
mutant. 
 
Figure 50 – AIF expression and immunolocalization analysis on stable cell line expressing WT, S375G, and S375E TDP-
43. A) Western blot analysis of AIF1 expression in the stable clones (upper panel) and its quantification and statistical 
analysis (lower panel) performed with unpaired t-test using GraphPad software (GraphPad Software, La Jolla California, 
USA). Tubulin was employed as a standard loading control B) immunolocalization analysis of AIF1 protein. In blue are 
stained the nuclei with Hoechst; in red mitochondria signal was performed with MitoTracker Red CMXRos kit 
(ThermoFisher Scientific, Waltham, Massachusetts, USA); in green AIF1 signal was stained with α-mouse Alexafluor 
488. The merged channels are also reported. 
In the future, in order to better identify all the changes in gene expression mediated 
by these mutants we plan to perform RNA sequencing analysis. This will allow us, for the 
first time, to pinpoint exactly all the genes that are misregulated in the presence of a disease-
associated mutation that changes only one aminoacidic out of the 414 which compose TDP-
43. Of course, as this mutation has only been described in one individual, it is unlikely that 
the results will represent the basis for a therapeutic approach that might be specific just for 
this change. However, my hope that RNA sequences study will allow to identify pathways 
and genes that could mediate the toxicity of TDP-43 in neuronal cells irrespective of the 
presence or not of the mutation. In the future, in fact, my aim will be to test these 
genes/pathways for their ability to rescue the toxic effects of TDP-43 also in cells from 
sporadic patients where the protein is almost always in the wild-type condition. 
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4.2 Involvement of TDP-43 in neurological defects of Niemann-Pick type 
C: new therapeutic target for the disease 
As already discussed in the introduction, RNA binding proteins like TDP-43 can be 
involved in the appearance of the neuronal degeneration features in lysosomal storage 
disorders (Janas et al., 2016; Jellinger, 2009; Potashkin and Meredith, 2006). A clear 
example of this is represented by the case of Niemann-Pick type C (NPC) where it was 
reported by Andrea Dardis and colleagues that TDP-43 can be found mislocalized and 
hyperphosphorylated in the cytoplasm in different models (Dardis et al., 2016).  Following 
their conclusions, I further extended and characterized the differentially expressed genes 
occurring in NPC disease due to TDP-43 mislocalization. As for the S375G mutation, the 
aim of this work has been to characterize the cellular events that become misregulated upon 
aberrant phosphorylation and localization of TDP-43. In turn, this will hopefully be able to 
provide novel targets for therapeutic intervention and biomarker analysis. 
 
4.2.1 RNA sequencing analysis on human NPC disease model 
To reach our goal, we sent for RNA sequencing to Novogene (Novogene Co., Ltd, 
Beijing, China), eight RNA samples derived from neuronal cells differentiated from human 
multipotent adult stem cells isolated from the skin (hSKIN-MASCs) of NPC patients and 
healthy controls (Fig.51). These cells were differentiated to human neuronal cells using a 
protocol employed in a previous work by Dardis’s lab and described in detail in the Material 
and Methods section (Bergamin et al., 2013). As shown in Figure 51, the differentiated 
neuronal cells from healthy individuals (left) and NPC patients (right) already displayed a 





Figure 51 – Multipotent stem cells isolated from skin biopsies reprogrammed in neurons, in this figure are reported the 
healthy controls and the patients. Figure in collaboration with Stefania Zampieri and Andrea Dardis. 
The samples’ details, sent for the RNA sequencing analysis, are reported as follows 
in table 22. 
Sample Mutations Concentration 
CTR-1 WT WT 1171,18 
CTR-2 WT WT 728,06 
CTR-3 WT WT 894,15 























Table 22 – Controls (CTR) and patients (PT) details in terms of allele mutations and sample concentration. 
127 
 
Before sending the RNA, I performed a quality control analysis using the QIAxcel® 
RNA QC Kit (QIAGEN) (Fig.52). 
 
Figure 52 – RNA quality check. Qiaxcel gel image of the RNA run. 
As reported in Figure 53, a cluster analysis was performed between the two groups 
in order to estimate the expression pattern of differential expressed genes and it confirmed 
that the gene profile of the differentiated neurons from the patients were very different from 
each other. As supported by the Venn diagram (Fig.53B), a total of 799 genes were 
differentially expressed between NPC patients and healthy controls out of the more 12.000 
that were tested in the RNA sequence analysis. 
 
Figure 53 – Gene expression analysis of differentially expressed genes. A) Cluster analysis of differential expressed 
genes: in blue are represented the genes with low expression, in red the highly expressed genes. B) Venn diagram 
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representing the number of different expressed genes between the two groups. The overlapping region is showing the 
number of genes that are commonly expressed (Novogene report). 
These genes were then sorted for the p-value adjusted (pAdj<0.05) and for the fold 
change (FC>1.3 for the up-regulated genes; FC<0.7 for the down regulated genes). They 
were then plotted in a Volcano plot (Fig.54) showing that approximately 300 genes were 
found up-regulated, and 500 genes were down-regulated. 
 
Figure 54 – Volcano plot representing the 799 differentially expressed genes. In green are reported the down-regulated 
genes, and in red the up-regulated targets. 
A more detailed analysis was carried out in order to better understand the cellular 
system involved, the genes potentially associated in diseases, and the involved pathways. 
As shown in Figures 55 and 56, a Gene Ontology (GO) and a Kyoto Encyclopedia 
of Genes and Genomes (KEGG) enrichment analysis were carried out. This analysis 
showed that many GO terms referred to genes involved in metabolic pathways (Fig.55), a 
result that is consistent with NPC pathogenesis. Moreover, the GO analysis also detected 
genes linked to locomotor behavior, confirming the hypothesis of a neurological impairment 




Figure 55 – GO enrichment analysis. The number of counts were plotted considering the p-value adjusted (Novogene 
report). 
These results were also confirmed by the KEGG analysis, in which the main term to 
be represented was axon guidance, again in agreement with the neuronal degeneration 
observed in the disease (Fig.56). 
 
Figure 56 – KEGG enrichment analysis. The number of counts were plotted considering the p-value adjusted (right part 
of the panel). A deeper analysis on axon guidance term was reported (Novogene report). 
Clearly, many of these deregulated gene expressions were due (directly or 
indirectly) to the absence of the NPC1 protein. Therefore, it would be incorrect to think that 
they become misregulated simply because TDP-43 in NPC is mislocalized to the cytoplasm 
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and aberrantly phosphorylated. Then, in order to find a relationship between the Niemann 
Pick type C disease and TDP-43 mis-localization and hyperphosphorylation, we decided to 
merge the data emerged from the NPC RNA sequencing with the data obtained from a 
previous RNA sequencing analysis carried out in our lab on SHSy5Y cells silenced for TDP-
43 (Fig.57) (Cappelli et al., 2018). As a comparison with the NPC analysis, the data shown 
in Figure 57 give the result of this previous analysis where 3533 genes were differentially 
expressed between the cells silenced for TDP-43 and the control (siLUC); around 33% of 
the genes were down regulated, and the 67% were up regulated. From this analysis, it 
emerged that many genes involved in different pathways, especially related to 
neurodegeneration, as well as to inflammation, became dysregulated (Cappelli et al., 2018; 
Appocher et al., 2017). 
 
Figure 57 – Volcano plot representing the RNA sequencing data on SHSy5Y silenced for TDP-43. These data were 
extrapolated form the RNA sequence performed in 2017 after the paper of Appocher and colleagues (Appocher et al., 
2017). Analysis performed by Sara Cappelli: data reported in her PhD thesis titled “Role of TDP-43 and hnRNP proteins 
in the regulation of different RNA targets”, published by the Open University in 2019 
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As a result, the NPC RNA sequencing and the RNA seq on SHSy5Y cells with 
silenced TDP-43 data were merged in a volcano plot and from this combination, a total of 
64 genes were discovered to be commonly misregulated. As apparent from this analysis, 
several of the most highly misregulated genes in NPC cells (LCP1, EPDR1, SHANK1, 
CDH18) are also regulated by TDP-43 levels. In particular, LPC1 is related to NF-kappa B 
signaling that has already been shown to play a role in the activation of apoptosis in NPC 
cells (Zampieri et al., 2009) whilst others are well known to play a role in synaptic activation, 
adhesion, axon growth, etc. (SHANK1, CDH18). Taken together these results strongly 
suggest that TDP-43 mislocalisation in patient cells could have a pathological effect on NPC 
neuronal cells function and survival. 
 
 
Figure 58 – Volcano plot of merged data between NPC RNA seq, and SH-SY-5Y cells silenced for TDP-43. The data 
were sorted for the p-value adjusted (pAdj<0.05) and for the fold change (FC>1.3 for the up-regulated genes; FC<0.7 for 
the down regulated genes). 
 
4.2.2 RNA sequencing gene expression validation 
Starting from the results obtained by merging the two RNA sequencing data-sets 
(Fig.58), I selected some genes based on their misregulation levels and their cellular 
function in order to validate the sequencing through Real Time Quantitative PCR. As 
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reported in Table 23, four down regulated genes and five up regulated genes were chosen 
for the validation analysis. 
Gene 
Name 
Gene Description Gene Function 
CDH18 Cadherin 18  
Type II classical cadherin from the cadherin superfamily 
of integral membrane proteins that mediate calcium-
dependent cell-cell adhesion. This particular cadherin is 
expressed specifically in the central nervous system and 
is putatively involved in synaptic adhesion, axon 
outgrowth and guidance.  
DCLK1 Doublecortin Like Kinase 1 
The protein encoded bind microtubules and regulate 
microtubule polymerization, and shows homology to 
Ca2+/calmodulin-dependent protein kinase mediating 
multiple protein-protein interactions. This protein is 
involved in several different cellular processes, including 
neuronal migration, retrograde transport, neuronal 
apoptosis and neurogenesis. This gene is up-regulated by 
brain-derived neurotrophic factor and associated with 
memory and general cognitive abilities.  
DEPTOR DEP Domain Containing MTOR Interacting Protein 
Diseases associated with DEPTOR include Glycine N-
Methyltransferase Deficiency and Metaphyseal 
Chondrodysplasia, Jansen Type. Among its related 
pathways are PI3K / Akt Signaling and Autophagy. 
CDON Cell Adhesion Associated, Oncogene Regulated 
This protein is a member of a cell-surface receptor 
complex that mediates cell-cell interactions between 
muscle precursor cells and positively regulates 
myogenesis.  
LGR4 
Leucine Rich Repeat 
Containing G Protein-
Coupled Receptor 4 
It is a G-protein coupled receptor that binds R-spondins 
and activates the Wnt signaling pathway. This Wnt 
signaling pathway activation is necessary for proper 





Upon stimulation by inositol 1,4,5-trisphosphate, this 
receptor mediates calcium release from the endoplasmic 
reticulum. Mutations in this gene cause spinocerebellar 
ataxia type 15, a disease associated with a 
heterogeneous group of cerebellar disorders. 
LCP1 Lymphocyte Cytosolic Protein 1 
Plastins are a family of actin-binding proteins. Diseases 
associated with LCP1 include B-Cell Non-Hodgkin 
Lymphoma and Noonan Syndrome 1. Among its related 
pathways are NF-kappaB Signaling.  
SHANK1 SH3 And Multiple Ankyrin Repeat Domains 1 
 Members of this family act as scaffold proteins that are 
required for the development and function of neuronal 
synapses.  
EPDR1 Ependymin Related 1 
 Type II transmembrane protein that is similar to two 
families of cell adhesion molecules, the protocadherins 
and ependymins. This protein may play a role in calcium-
dependent cell adhesion. This protein is glycosylated, and 
the orthologous mouse protein is localized to the 
lysosome. 
Table 23 – Selected genes for the RNA-sequencing validations. In red are highlight the up regulated genes; in green the 
down regulated items. 
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The validation was performed on neuronal cells differentiated from human multipoint 
adult stem cells isolated from the skin from NPC patients and healthy controls. Following the 
previous analysis, I tested three control (WT) and three NPC samples (NPC) in quantitative 
real-time PCR. As shown in Figure 59, differences in gene expression for all these genes 
are all statistically significant in comparison to the healthy control. Moreover, I included TDP-
43 in the analysis that seemed to be slightly up-regulated in the NPC cells, presumably 
owing to the fact that a heavy mislocalization in the cytoplasm would induce the 
autoregulation mechanism to increase protein production in order to maintain normal levels 
in the nucleus. 
 
Figure 59 – Quantitative real-time PCR preliminary result on RNA sequencing validation. The statistical analysis was 
performed on three independent experiments each containing three technical replicates. The relative normalized 
expression levels were plotted in a grouped table and an unpaired t-test was performed using GraphPad software 
(GraphPad Software, La Jolla California, USA). In order to better visualize all the plotted data, the x axe was plotted in 
log10 scale. 
 
4.2.3 RNA sequencing functional validation 
Following the RNA sequencing gene expression validation, I performed a functional 




4.2.3.1 RNA immunoprecipitation assay 
In order to establish whether direct binding of TDP-43 exists with the selected 
targets, an RNA immunoprecipitation assay was performed. As reported in Figure 60, 
ITPR1 and EPDR1 mRNAs were significantly enriched following TDP-43 
immunoprecipitation compared to IgG control. The occurrence of correct transfection was 
controlled by Western blot, using tubulin as a loading control. 
 
Figure 60 – RNA immunoprecipitation assay on down regulated genes. A) RNA immunoprecipitation analysis derived 
from quantitative real-time PCR. The obtained data were plotted in a grouped table and a multiple t-test was performed 
using GraphPad software (GraphPad Software, La Jolla California, USA). B) Western blot analysis was performed to 
check the transfection efficiency. Α-flag M2 antibody was performed to check the presence of transfected TDP-43. 
Tubulin was used as standard loading control. 
The same experiment was performed for the up-regulated selected genes. As for 
the down-regulated targets, correct transfection was tested first by western blot and the 





Figure 61 – RNA immunoprecipitation assay on up regulated genes. A) RNA immunoprecipitation analysis derived from 
quantitative real-time PCR. The obtained data were plotted in a grouped table and a multiple t-test was performed using 
GraphPad software (GraphPad Software, La Jolla California, USA). B) Western blot analysis was performed to check the 
transfection efficiency. Α-flag M2 antibody was performed to check the presence of transfected TDP-43. Tubulin was 
used as standard loading control. 
One question that may arise from these results is to determine the binding sites of 
TDP-43 for these mRNAs. From previous studies, it has been known that TDP-43 binds 
specifically the mRNA sequences that  are UG/TG rich (Y. M. Ayala et al., 2008; Buratti and 
Baralle, 2001). Using Ensemble Genome Browser (Ensembl genome browser 102), a brief 
research of TG stretch was performed for ITPR1, EPDR1, and DCLK1 genes. In all three 
cases, TG stretches could be found at exon/intron critical sites as well as in the flanking 
untranslated regions (5’ and 3’UTRs). In particular, for the EPDR1 gene I could see that the 
3’UTR is strongly enriched in TG stretches. At the moment, functional experiments have not 
yet been performed to validate these potential binding sites. In the future, this will probably 
be necessary to determine exactly how TDP-43 direct binding can affect mRNA processing 
in these genes (i.e., splicing, stability, transport) and therefore their expression. 
 
4.2.3.2 Down-regulated genes functional analysis 
In order to establish a functional significance for the selected genes, I tested in 
SHSy5Y cell line the effect of up- or down-regulating the expression of these genes by 
silencing or overexpression. 
I started the analysis with the down regulated genes because the production of a 




4.2.3.2.1 Down-regulated genes functional analysis: LDH release assay 
Following the previous observations, I decided to test the following genes: LCP1, 
EPDR1, SHANK1, ITPR1). Then, after 24, 48, and 72 hours after siRNA treatment the 
cellular LDH levels were measured together with the gene expression levels in order to 
check the silencing efficiency. As shown in Figure 62, all the genes were significantly 
silenced compared to the negative control that was represented by the siRNA against the 
Luciferase (siLUC) (Fig.62A, B, and C right part). In the left part of all panels, cellular toxicity 
was reported compared to the control (siLUC). As shown in this figure, only ITPR1 silencing 




Figure 62 – LDH release assay. The absorbance at 485 nm is reported, and three-time laps (24 (A), 48 (B), and 72 (C) 
hours) were studied. In all panels the gene expression upon silencing tested by quantitative real-time PCR is also 
reported. The statistical analysis was performed on three independent experiment with multiple comparison one-way 




4.2.3.2.2 Down-regulated genes functional analysis: TDP-43 and pTDP-43 
immunolocalization analysis upon ITPR1 knockdown 
Based on these preliminary results, ITPR1 seemed to be the most promising target 
to further characterize in terms of its relationship with TDP-43. In order to establish a 
possible bi-functional correlation between ITPR1 and TDP-43 the localization of TDP-43 
phosphorylated S409/S410 form was tested upon ITPR1 knockdown. As reported in Figure 
64, following ITPR1 silencing the localization of TDP-43 was more cytoplasmic and its 
phosphorylated form was even more expressed compared to the control. 
 
 
Figure 63 – TDP-43 and pS409/S410 TDP-43 immunostaining upon ITPR1 silencing. A) TDP-43 and pS409/410 TDP-43 
staining for the control (siLUC) and for ITPR1 knockdown. The merged images are showed. B) Western blot control of 
ITPR1 silencing efficiency. C) Quantitative real time PCR test of ITPR1 silencing performed in three independent 
experiments. The results were plotted in column table and a T-test analysis was performed using GraphPad software 














The role of PTMs in controlling both physiological and pathological status of different 
proteins has been studied a long time in order to improve diagnostic, prognostic approaches 
and also for identifying new specific targets for a list of many heterogeneous disorders, 
including neurodegeneration (Buratti, 2018; Pagel et al., 2015).  
In the work for my thesis, I have focused on TDP-43 phosphorylation that seems to 
play an important role in different neurodegenerative disorders and appears as a common 
aberrant feature in the ALS/FTD type of diseases as well as in metabolic disorders such as 
Niemann Pick C (Buratti, 2018; Dardis et al., 2016; Neumann et al., 2009; Weihl et al., 2008). 
In all of these pathological contexts, the balance between physiological and pathological 
status is very delicate, and for this reason I studied two different models in which TDP-43 
phosphorylation is impaired: a disease-associated TDP-43 mutation in a particularly early-





5.1 Characterization of TDP-43 mutation in an ALS case affecting a 
potential phosphorylation site 
Regarding ALS disease, together with a group in Indiana/Kansas University, I 
described for the first time a novel mutation in TDP-43 affecting a Serine residue changing 
in a Glycine in position 375 (S375G) that was present in a particularly early-onset ALS case, 
with upper and lower motoneuron involvement, and the presence of hyperphosphorylated 
TDP-43. 
As already described in the Introduction chapter, TDP-43 mutations are quite rare 
events and it is not always easy to prove a clear relationship between the discovered variant 
and the disease (Buratti, 2015). However, looking at the literature, a lot of mutations with a 
clinical significance have been described over the years and many of them are affecting a 
potential phosphorylation site: by removing a potential site of phosphorylation, by inserting 
a Serine or a Threonine, thus adding a novel hypothetical phosphorylated residue, or by 
missense substitutions that introduce negatively charged aminoacids such as Glutamic or 
Aspartic acid, thus mimicking a phosphorylation event (Buratti, 2018). All of these alterations 
can change the protein-protein interaction profile of TDP-43, increase its aggregation, and 
affect half-life or its cytoplasmic localization. Taken together, these observations lead to the 
hypothesis that phosphorylation could play a key role between the physiological and 
pathological balance (Buratti, 2015, 2018; Newell et al., 2018).  
In many respects, the S375G mutation that I described in this work could change 
any of these features and its molecular/functional analysis. It is therefore interesting to 
compare our results with the effects of other mutations already studied in literature that could 
involve changes in the phosphorylation status of TDP-43.  
Starting with the disruption of a potential phosphorylation site, Corrado and 
colleagues in 2009 described a novel mutation (S396L) with a deleterious effect on the 
protein structure that was leading to the formation of low molecular weight fragments 
(around 32 KDa), probably after affecting TDP-43 stability (Corrado et al., 2009). In keeping 
with these results, it was interesting to note that the S375G mutation can also affect the 
protein structure and stability, but instead of promoting fragmentation it was promoting the 
TDP-43 self-association and its nuclear retention (Newell et al., 2018).  
In another occurrence, Xiong and colleagues described a Serine changed to an 
Asparagine in position 292 and predicted the variation to be deleterious for protein function, 
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although no functional validation was provided (Buratti, 2015; Xiong et al., 2010). Similarly, 
the S375G mutation is disrupting the normal protein functions, in particular regarding the 
role played by TDP-43 in cell cycle regulation. Moreover, the structural analysis of S375 
surrounding residues suggested that the ability of these mutations to alter TDP-43 
localization in the nucleus (or in the cytoplasm for its phosphomimic mutant) could be 
specifically connected to S375 potential phosphorylation (Newell et al., 2018).  
Nearer to the 375 position, previous works identified the insertion of a Threonine 
instead of a Serine in position 387. In this work, Solski and colleagues showed that S387T 
was inducing loss of nuclear TDP-43, correlating well with the formation of cytoplasmic 
inclusions upon induced stress (Solski et al., 2012). The Threonine is also a potential 
phosphorylated residue, and upon stress condition this post-translational modification can 
become aberrant (Buratti, 2018). This result is consistent with the one obtained with our 
S375E phosphomimic mutant, in which its cytoplasmic presence, compared to WT protein, 
was even more persistent upon sodium arsenate induced stress conditions (Newell et al., 
2018). This is somewhat similar to the results of  another mutations, A315E that was shown 
to increase TDP-43 cytoplasmic amount of TDP-43 following structural modifications (Zhu 
et al., 2014). 
Importantly, many mutations that create a novel potential phosphorylated site were 
also described in literature to be related with aggregation. For example, N390S mutation 
was described to enhance TDP-43 aggregation and insolubility and the G295S mutation 
was found to induce twisted amyloid-like fibers that increased the aggregative status of TDP-
43 (Jo et al., 2020; Gendron et al., 2013). These results are in contrast with our mutants, in 
which the protein seems to remain mainly soluble with the exception of the S375E 
phosphomimic upon arsenate treatment. Moreover, the presence of the negative charge 
promotes the disruption of the amyloid-like structure in the S375E mutant. This difference is 
interesting because it shows that mutations in TDP-43 phosphorylation may have a great 
variety of effects and will not necessarily overlap with each other. This is also confirmed by 
the description of other mutations such as R361S and N390S that were increasing the CTD 
truncated forms (Gendron et al., 2013). Also, in this case, this result differs from the one 
obtained in the S375E phosphomimic mutant where no truncated forms were revealed both 
in the transient transfection experiments as well as in the stable cell line. 
Finally, another example is the A382T mutation that was described to induce a 
reduction in the ability of cells to respond to cellular stress leading to a TDP-43 loss of 
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function. There are also in this case some similarities with our S375 changes in terms of 
responding to cellular stress. However, there are also important differences as S375 can 
become toxic and aberrant in the pathological status through a gain of function mechanism 
(Newell et al., 2018; Orrù et al., 2016). 
As shown from all these examples, the disruption or the insertion of a novel 
phosphorylated site can lead to different conditions. Due to the great variability of the effects 
observed, however, it is important to study how the potential phosphorylation status of each 
mutations is influencing the protein functions both in physiological, as well as in pathological 
conditions. In order to perform this, the employment of a phosphomimic variant is not new 
in the field, and in literature are reported many examples using this technique (Wang et al., 
2018; Li et al., 2017; Kim et al., 2015; Brady et al., 2011; Guo et al., 2011). The single 
negative charge carried by the Glutamic Acid (or the Aspartic Acid) is sufficient to mimic the 
phospho-modification. I also took advantage of this technique in order to clarify the strong 
toxicity of the S375G mutation and its nuclear retention, assuming that the phosphorylation 
of this residue could balance the nuclear-cytoplasmic shuttle of TDP-43 (Newell et al., 2018). 
Therefore, I compared the two opposite conditions, such as the lack of the Serine (S375G) 
with its impossibility to be phosphorylated, and its constitutive aberrant phosphorylation 
imposing the negative charge of the Glutamic Acid (Newell et al., 2018). As already 
mentioned, the transiently transfected S375E phosphomimic mutant was more localized in 
the cytoplasm, but without compromising the splicing capability of the protein, an effect that 
could be explained due to the amount of S375E TDP-43 persisting in the nucleus, which 
was presumably sufficient to drive correct pre-mRNA processing. Due to a molecular 
dynamic simulation, the different subcellular localization within the two mutants was 
characterized: while the WT and the S375G TDP-43 form presented a strong amyloid-like 
structure, the phosphomimic appeared unstable due to the presence of the negative charge 
(Newell et al., 2018). The disruption of TDP-43 assembly was also described by Wang and 
colleague in 2018, using a phosphomimic of an N-terminal Serine in position 48 (Wang et 
al., 2018). This is supporting the idea that the phosphorylation of the protein could induce a 
destabilization of TDP-43 polymerization and its cytoplasmic shuttle.  
In addition, it is still unclear which kinases are responsable for this phosphorylation 
event. In general, TDP-43 phosphorylation is probably linked to cellular stress if we consider 
that TDP-43 was described to strongly regulated by the MAPK/ERK kinase. Also in this case, 
phosphomimic variant were employed to study the response upon TDP-43 phosphorylation. 
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In particular the T153 and Y155 residues, identified as MEK phosphorylated sites, were 
substituted with a phosphomimic residue, increasing the heat shock response, that normally 
occures as a survival reaction to toxic conditions (Li et al., 2017). In contrast with the S375E 
phosphomimic, the T153 and Y155 phosphorylation could be affecting the GU- stretch 
recognition, imparing TDP-43 splicing capability (Newell et al., 2018; Li et al., 2017). 
In addition, TDP-43 aberrant phosphorylation can become toxic and irreversible in 
disease condition. Supporting this idea, the negative charge of the S375E mutant is inducing 
cellular toxicity (Newell et al., 2018). This result is also supported by the literature, in which 
phosphomimic substitution have a toxic effect on the cells. For example, Ki Yoon Kin and 
colleagues studied three different TDP-43 phosphomimic mutants (S379E, S403/404E, and 
S409/410E) that were able to reduce Drosha stability, preventing protein-protein interaction 
and compromising TDP-43 function, and inducing neurotoxicity in Neuro 2A cell line (Kim et 
al., 2015). In comparison with this work, the S375E phosphomimic mutant did not show any 
compromise in the protein function that concerns TDP-43 splicing capability. However, 
toxicity was observed that may be linked to changes in the cell cycle, as reported in the 
stable clones’ experiments. 
Taken together, the obtained results showed that the phosphorylation of S375 might 
be a key aspect of TDP-43 assembly and it could play an important role in the nuclear-
cytoplasmic balance. The potential phosphorylation of the Serine in position 375 could be 
involved in the physiological phosphorylation of TDP-43, promoting its dissociation and the 
cytoplasmic transport, which is necessary for TDP-43 to carry on its functions. Conversely, 
in the S375G mutant the lack of this Serine residue was shown to promote cellular toxicity 
because this TDP-43 form was more confined in the nucleus, presumably affecting 
cytoplasmic physiological activities. Moreover, the relevance of the S375 residue could also 
play a role in pathological TDP-43 phosphorylation, as shown in the sodium arsenate 
treatment of the transfected cells with the S375E phosphomimic. 
In order to better clarify this physiological/pathological subtle balance, I created 
stable clones expressing the WT, S375G, and S375E (phosphomimic) TDP-43 forms. Again, 
the stable clones creation for TDP-43 functional study was already employed in the past 
permitting the study of protein aggregation (Budini et al., 2012). As with transient 
transfections, no significant changes were reported in splicing, autoregulation, or 
aggregation in these stable cell lines. However, a cell cycle analysis of the stable clones 
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showed that the number of cells in the G2 phase decreased in the two mutants compared 
to the WT that could be linked with activation of apoptosis. 
It is known that the apoptosis is one of the key processes promoting 
neurodegeneration (Ekshyyan and Aw, 2005). In particular, the mitochondria apoptotic 
signal is one of the key players that mediates the proapoptotic signaling in 
neurodegeneration (De Conti et al., 2015; Shangguan et al., 2014; Shibata et al., 2009; 
Krantic et al., 2007; Ekshyyan and Aw, 2005; Kermer et al., 2004; Candé et al., 2002). As 
already reported, the CTD fragmentation is leading to a G2 phase drop compromising 
cellular survival and leading to apoptosis (Yamashita et al., 2014). In this contex, considering 
that TDP-43 aberrant phosphorylation is one of the early responses to cellular stress and 
that TDP-43 neurotoxicity can trigger the mitochondria pathway, we are considering this G2 
phase decrease potentially linked to the mitochondria stress signaling, leading to cell death 
response. In particular the Apoptosis-inducing factor 1 (AIF1), a mitochondrial protein, was 
described to be consistently involved in neuronal death  (Shibata et al., 2009; Krantic et al., 
2007; Candé et al., 2002). Based on these assumptions, I performed an immunolocalization 
analysis of AIF1 mitochondrial protein, and I observed that AIF1 protein in the S375G and 
the S375E mutants was not confined anymore in the mitochondria, but it was found diffused 
inside the cell, especially in the nucleus. This is consistent with the literature and could 
represent a sign of an early apoptotic phase where the expression of these TDP-43 mutated 
forms could lead to mitochondria stress signaling, resulting in AIF1 release and its shuttle 
from the cytoplasm to the nucleus where it could induce an apoptotic signal (Candé et al., 
2002). Further analysis will be required in the future to better characterize the involved 
pathways, and maybe mitochondrial stress could be used as a therapeutic strategy or as an 
early marker for the disease.  
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5.2 Involvement of TDP-43 in neurological defects of Niemann-Pick type 
C 
Disfunction of the RNA metabolism or the involvement of RNA binding proteins in 
lysosomal storage disorders, is one of the putative cause of the neurodegenerative features 
related to this disorders (Paron et al., 2020). Considering TDP-43 role in other 
neurodegenerative disorders, in 2016 this was studied by Andrea Dardis and colleague 
relating to NPC disease. They found  TDP-43 mislocalized and hyperphosphorylated in 
different NPC models (Dardis et al., 2016). This work prepared the foundation for my study, 
trying to better understand the molecular mechanisms that lead to TDP-43 pathological 
involvement and its phosphorylation in this disorder. For this reason, I performed an RNA 
sequencing analysis on human NPC cellular model, and I compared it to the list of changes 
detected in neuronal SHSy5Y cells depleted for TDP-43. From this analysis, 64 genes were 
commonly misregulated within NPC RNA sequencing and the one performed on SHSy5Y 
cells upon TDP-43 silencing. Between these 64 genes, I selected and validated some of 
them basing on their misregulation rate, and their cellular function. In particular, LCP1 and 
ITPR1 were already described to be involved in NPC disease. In particular LCP1 pathway 
is related to NF-kappaβ signaling, already known to induce apoptosis in NPC disease 
(Zampieri et al., 2009). ITPR1 variant was described to worsen the ataxia phenotype in a 
NPC patient, consistently with ITPR1 involvement in cerebellar ataxia 15 (Zeiger et al., 
2018). Moreover, ITPR1 is also involve in calcium homeostasis, as well as DCLK1 and 
CDON. These two genes are able to modulate neuroplasticity, axon outgrowth and 
guidance, neuronal apoptosis and neurogenesis, and neuronal migration through calcium 
homeostasis. Instead, EPDR1 is involved calcium homeostasis to promote cellular 
adhesion. SHANK1 is also involved in neuronal pathways, like the development of 
synapses, and CDON regulates myogenesis. Like ITPR1 and DCLK1, also DEPTOR and 
LGR4 are involved in important cellular pathways, such as the PI3K/Akt and the Wnt 
signaling, respectively (GeneCards - Human Genes | Gene Database | Gene Search). 
After the validation, I performed a functional analysis testing the RNA 
immunoprecipitation of the selected genes within TDP-43 overexpression, in order to 
establish a link between TDP-43 and the selected genes. This analysis showed ITPR1, 
EPDR1, and DCLK1 enrichment, leading to the hypothesis that the mRNAs of these three 
targets were directly bound by TDP-43. Indeed, for all these three genes, TG stretches were 
found both in exons/introns critical sites as well as in the untranslated regions. This supports 
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the idea that TDP-43 could be involved in ITPR1, EPDR1, and DCLK1 regulation, inducing 
alternative splicing, by binding to exons/introns critical sites; or in mRNA degradation or 
instability, by recognizing TG stretches in the untranslated regions. Further analyses will be 
necessary in order to clarify the mechanism of action. 
Together with the RNA immunoprecipitation assay, I performed a functional analysis 
on the down-regulated genes by testing their cellular toxicity and measuring the LDH release 
in the medium after silencing the down regulated genes of interest. From the LDH release 
cytotoxicity assay, just ITPR1 gene showed a cytotoxic effect at 48 and 72 hours, adding 
another evidence to the RNA immunoprecipitation assay, and leading to the hypothesis that 
ITPR1 could be somehow involved and linked to TDP-43 neuropathogenesis. Indeed, 
calcium pathways and Cyclic adenosine monophosphate (cAMP) homeostasis related to 
oxidative stress, were already described to be associated biomarkers in another 
neurodegenerative disorder, such as FTLD (Palluzzi et al., 2017). In addition, different 
papers were published coupling TDP-43 neuronal toxicity and its sub-cellular localization 
with ITPR1 as a modifier of this condition (Zhan et al., 2013; Kim et al., 2012). Moreover, 
supporting our results, ITPR1 was already described in literature as a down-regulated item 
upon TDP-43 knockdown (Štalekar et al., 2015; Polymenidou et al., 2011). Also, ITPR1 
potentially involvement in NPC was described by William Zeiger and colleagues, reporting 
a NPC patient with a novel ITPR1 variant that leads to an autosomal dominant 
spinocerebellar ataxia that worsen the phenotype (Zeiger et al., 2018). Therefore, ITPR1 
down regulation could be a phenotype modifier in NPC disease, related to TDP-43 
misregulation and hyperphosphorylation. Based on these preliminary results, I performed 
an immunolocalization analysis showing that ITPR1 knockdown was promoting TDP-43 
cytoplasmic localization and its phosphorylation. This could be an important starting point 
for investigating strategies that will allow the rescue of proper TDP-43 localization in the 
nucleus and thus recovery of proper gene expression, in particular kinase inhibitors 
compounds already approved for clinical applications. 
Further experiments should be performed in order to test also the up-regulated 
genes and the effects of their overexpression. In addition, there is also work that remains to 
be done with regards to better characterizing the aberrant phosphorylation process of TDP-
43 in NPC. In my experiments, I have focused on the well-known S409/S410 
phosphorylation sites that are also found in the ALS/FTD pathway. However, it is also 
possible that in the NPC model the aberrantly localized TDP-43 may carry some novel 
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phosphorylation events that have yet to be described. To address this issue, I therefore plan 
to immunoprecipitated TDP-43 from our NPC model cell lines and perform mass-spec 
analysis to identify the phosphorylation sites of TDP-43 in NPC cells. To do this, we will use 
the mass-spec facility at ICGEB that has a long-standing expertise in this kind of analysis. 
Another question that remains open is the identification of kinases that are involved 
in the phosphorylation of TDP-43 in NPC. Are they the same or are they different from 
ALS/FTD disease? To address this issue, I plan to overexpress various kinases in our model 
cell lines to address the mislocalization properties of phosphorylated TDP-43. For example, 
this could be done using lentiviral vectors with genes cloned under the control of ubiquitous 
or neuron-specific promoters (for example, HB9, a lower MN-specific transcription factor). 
In parallel, from the SIGMA MISSION shRNA library I might obtain lentiviruses carrying three 
different shRNAs that specifically target selected human kinases. After target gene 
overexpression or silencing, any modifications to the phosphorylation status and behavior 















Following the discussion and the reported results, the two disease models have 
revealed distinct aspects that could be employed for novel strategies and to add new 
information regarding TDP-43 pathogenic mechanism. 
First of all, the work I have performed has pointed out that the study of a single point 
mutation can lead to discover new features of proteins, that might represent a novel link to 
disease. The analysis of this Serine in position 375, revealed its relevance in both 
physiological and pathological conditions, opening a new window in cell cycle/apoptosis 
related phosphorylation. In conclusion the S375 phosphorylation seemed to promote the 
cytoplasmic shuttle of TDP-43 protein in physiological conditions; instead, the pathological 
status was induced by the lack of phosphorylation as well as its abnormal modification. This 
could be linked to mitochondria apoptotic pathway, and in future it could be exploited as a 
novel therapeutic target for ALS and, more in general, for neurodegenerative disorders. 
Following this, the importance of phosphorylation in regulating TDP-43 functions 
has been highlighted by my study on its pathological role in Niemann Pick type C. In 
particular, this work has allowed the identification of a novel potential modifier, namely 
ITPR1. The downregulation of this gene seems to worsen the TDP-43 related phenotype, 
especially regarding the phosphorylation pattern of the protein. Further studies will therefore 
be performed to check if ITPR1 could possibly represent a potential target or biomarker of 
the disease not just NPC, but also other TDP-43 related neurodegenerative disorders. 
Moreover, ITPR1 involvement in kinase pathways could represent a novel target for already 
approved kinase inhibitors, as new strategies for the treatment of neurological disorders. 
 
In conclusion, this work is looking at phosphorylation as a common target between 
heterogenous neurodegenerative diseases, underlying the relevance of the 














For both models, further analysis will be necessary. 
To better understand the potential second modifiers of the 
physiological/pathological balance, an RNA sequencing analysis on the S375G and S375E 
stable clones will be performed. The results from this analysis could be interesting in order 
to add new information about what is regulating the toxicity of this specific PTM and to better 
characterize the cell cycle/mitochondrial apoptosis involvement. Moreover, the obtained 
data from this sequencing can then be merged with the one obtained with NPC with the 
hope of finding the common features that regulate the phosphorylation status. It will also be 
interesting to start analyzing the differences between ALS and NPC1, thus identifying 
specific characteristics relating to the different diseases. Moreover, the RNA sequencing 
data will add some functional information about the normal cell division/apoptosis signal, 
that could be rescued by treating the cells with small compounds known to be able to rescue 
the pathway, both in normal and in stress conditions. 
 
Regarding the NPC model, a lot is still needed to be added. First of all, the exact 
positions where TDP-43 binding with ITPR1, EPDR1, and DCLK1 is occurring should be 
clarified. This is important in order to establish how these genes are regulated by TDP-43, 
if they are alternative spliced or if TDP-43 induces mRNA destabilization by binding the 
untranslated regions. To study the potential alternative splicing, a deeper analysis of the 
RNA sequences should be performed. Moreover, specific primers should be designed on 
exons that could potentially undergo to TDP-43 splicing regulation.  On the other hand, the 
mRNA stability will be studied through transcription block, using for example actinomycin D. 
The half-life of the mRNA will be then tested with quantitative real time PCR, in order to 
check if TDP-43 binding is performing the mRNA degradation. 
Regarding ITPR1 analysis as a potential modifier of the disease, already clinical 
approved kinase inhibitors can be tested. Upon ITPR1 knockdown, kinase inhibitors will be 
administered to the cells and TDP-43 localization and phosphorylation will be monitored, in 
order to check if some of the compounds are able to rescue the wild-type phenotype. 
Moreover, the functional analysis on up-regulated genes will be performed. The 
selected targets will be cloned in the pCMV4 vector in frame with the flag tag. The 
overexpression in SHSy5Y ECACC cell line will be performed and their toxicity effects will 
be tested through the LDH release assay. Based on the results obtained with the cytotoxicity 
153 
 
experiment, together with the results following the RNA immunoprecipitation, we hope to 
find other potential targets that could represent another therapeutic option or it could add 
new information about the pathogenic mechanism. 
Finally, the two disease models could reveal different phosphorylation patterns and 
kinase involvement. In this context, it will be important to determine the putative TDP-43 
phosphorylated sites also in an NPC cellular model, in order to compare them with the ones 
found in ALS/FTLD spectrum (Kametani et al., 2016). Also, the identification of the kinases 
involved could help to address the mislocalization properties of phosphorylated TDP-43. 
This could be answered by overexpressing different kinases, under the control of ubiquitous 
or neuron-specific promoters, or to silence them by using shRNAs that specifically target 
selected human kinases. Both could be address by using lentiviral vectors. This will be 
useful to evaluate TDP-43 phospho-status and behavior and to potentially exploit it as a 
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